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Nitric  oxide  (NO)  is  an  endogenous  gaseous  signaling  molecule  produced  by  
three  NO  synthase  isoforms  (NOS1,  2,  3)  and  important  in  host  defense.  The  induction  of  
NOS2  during  bacterial  sepsis  is  critical  for  pathogen  clearance  but  its  sustained  
activation  has  long  been  associated  with  increased  mortality  secondary  to  multiple  
organ  dysfunction  syndrome  (MODS).  High  levels  of  NO  produced  by  NOS2  incite  
intrinsic  cellular  dysfunction,  in  part  by  damaging  macromolecules  through  nitration  
and/or  nitrosylation.  These  include  mitochondrial  DNA  (mtDNA)  and  enzymes  of  key  
mitochondrial  pathways  required  for  maintenance  of  normal  O2  utilization  and  energy  
homeostasis.  However,  animal  studies  and  clinical  trials  inhibiting  NOS2  have  
demonstrated  pronounced  organ  dysfunction  and  increased  mortality  in  response  to  live  
bacterial  infections,  confirming  that  NOS2  confers  pro-­‐‑survival  benefits.  Of  particular  
interest  here,  the  constitutive  NOS1  and  NOS3  have  been  linked  to  the  up-­‐‑regulation  of  
nuclear  genes  involved  in  mitochondrial  biogenesis  but  no  comparable  role  has  been  
described  for  NOS2.  Therefore,  I  hypothesized  that  NOS2  is  indispensible  for  host  
protection  but  must  be  tightly  regulated  to  ensure  NO  levels  are  high  enough  to  activate  
mitochondrial  and  other  pro-­‐‑survival  genes,  but  below  the  threshold  for  cellular  
damage.    
This  hypothesis  was  explored  with  two  major  Aims.  The  first  Aim  was  to  define  
the  role  of  NOS2  in  the  activation  of  mitochondrial  biogenesis  in  the  heart  of  E.  coli-­‐‑
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treated  mice.  The  second  was  to  investigate  the  ability  of  NOS2  to  be  transcriptionally  
regulated  by  an  enzyme  previously  shown  to  induce  mitochondrial  biogenesis,  heme  
oxygenase-­‐‑1  (HO-­‐‑1).    This  hypothesis  was  tested  using  an  in  vivo  model  of  sublethal  
heat-­‐‑killed  E.  coli  (HkEC)  peritonitis  in  C57B/L6  (Wt),  NOS2-­‐‑/-­‐‑,  and  TLR4-­‐‑/-­‐‑  mice.  
Additionally,  in  vitro  systems  of  mouse  AML-­‐‑12  or  Hepa  1-­‐‑6  cells  pretreated  with  HO-­‐‑1  
activators  or  Hmox1  shRNA  prior  to  inflammatory  challenge  with  lipopolysaccharide  
(LPS)  +/-­‐‑  tumor  necrosis  factor-­‐‑α  (TNF-­‐‑α).  For  the  first  Aim,  Wt,  NOS2-­‐‑/-­‐‑,  and  TLR4-­‐‑/-­‐‑  
mice  were  treated  with  HkEC  and  cardiac  tissue  analyzed  for  mitochondrial  function,  
expression  of  nuclear  and  mitochondrial  proteins  needed  for  mitochondrial  biogenesis,  
and  histological  expression  of  NOS2  and  TLR4  relative  to  changes  in  mitochondrial  
mass.    For  the  second  Aim,  Wt  mice  were  pretreated  with  hemin  or  carbon  monoxide  
(CO)  to  activate  HO-­‐‑1  prior  to  HkEC-­‐‑peritonitis.  Liver  tissue  in  these  animals  was  
evaluated  at  four  hours  for  HO-­‐‑1  induction,  Nos2  mRNA  expression,  cytokine  profiles,  
and  NF-­‐‑κB  activation.  Liver  cell  lines  were  pretreated  with  hemin,  CO-­‐‑releasing  
molecule  (CORM),  or  bilirubin  one  hour  before  LPS  exposure  and  the  Nos2  
transcriptional  response  evaluated  at  two  and  24  hours.  The  MTT  assay  was  used  to  
confirm  that  in  vitro  treatments  were  not  lethal.    
These  studies  demonstrated  that  HkEC  induced  mtDNA  damage  in  the  heart  that  
was  repaired  in  Wt  mice  but  not  in  NOS2-­‐‑deficient  mice.  In  KO  mice,  sustained  mtDNA  
damage  was  associated  with  the  reduced  expression  of  nuclear  (NRF-­‐‑1,  PGC-­‐‑1α)  and  
mitochondrial  (Tfam,  Pol-­‐‑γ)  proteins  needed  for  mitochondrial  biogenesis.  The  findings  
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thus  supported  that  NOS2  is  required  for  mitochondrial  biogenesis  in  the  heart  during  
Gram-­‐‑negative  challenge.  Evaluation  of  the  relationship  between  HO-­‐‑1  and  NOS2  in  
murine  liver  was  more  complex;  HO-­‐‑1  activation  in  HkEC-­‐‑treated  Wt  mice  attenuated  4-­‐‑
hour  Nos2  gene  transcription.  In  liver  cell  lines,  hemin,  CORM,  and  bilirubin  were  
unable  to  suppress  Nos2  expression  at  the  time  of  maximal  induction  (2  hours).  Nos2  
was,  however,  suppressed  by  24  hours,  suggesting  that  the  regulatory  impact  of  HO-­‐‑1  
induction  was  not  engaged  early  enough  to  reduce  Nos2  transcription  at  2  hours.    It  is  
concluded  that  NOS2  induction  in  bacterial  sepsis  optimizes  the  expression  of  the  
mitochondrial  biogenesis  transcriptional  program,  which  subsequently  can  also  be  
regulated  by  HO-­‐‑1/CO  in  murine  liver.  This  provides  a  potential  new  mechanism  by  
which  immune  suppression  and  mitochondrial  repair  can  occur  in  tandem  during  the  
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1. Introduction  and  Background  
1.1 Sepsis:  The  Clinical  Problem  
Sepsis  is  defined  by  the  systemic  inflammation  that  occurs  when  viral,  bacterial,  
or  fungal  pathogens  overwhelm  the  normal  host  barrier  defenses,  spread  systemically,  
and  trigger  a  robust  pro-­‐‑inflammatory  immune  response.    This  innate  immune  response  
is  necessary  for  the  host  to  clear  the  pathogen,  but  when  sustained  and  dysregulated,  
may  lead  to  cellular  damage  and  organ  dysfunction.  Each  year,  an  estimated  750,000  
Americans  develop  severe  bacterial  sepsis.  Of  these  patients,  some  200,000  die  from  
multiple  organ  dysfunction  syndrome  (MODS),  making  sepsis  the  leading  cause  of  
death  in  non-­‐‑cardiac  intensive  care  units  (ICUs)  and  10th  among  all-­‐‑cause  mortality  in  
the  United  States  [1,  2].  
Sepsis  can  quickly  progress  to  more  severe  stages  so  early  identification  and  
treatment  of  systemic  infections  is  critical  for  patient  survival.  The  diagnosis  of  sepsis  
requires  that  certain  clinical  criteria  be  met.    These  include  the  identification  of  a  source  
of  infection  in  connection  with  criteria  for  systemic  inflammatory  response  syndrome  
(SIRS).  SIRS  is  defined  by  the  presence  of  two  or  more  of  the  following  manifestations:  1)  
temperature  >38°C  or  <36°C;  2)  heart  rate  >90  beats  per  minute;  3)  respiratory  rate  >20  
breaths  per  minute  or  PaCO2  of  <32  mmHg;  and  4)  WBC  <4,000/mm2,  >12,000/mm2,  or  
>10%  immature  neutrophils  [3].  Sepsis  complicated  by  organ  dysfunction,  hypotension,  
or  hypoperfusion  is  called  severe  sepsis.    Furthermore,  when  hypotension  persists  despite  
aggressive  fluid  resuscitation  and  patients  require  hemodynamic  support  such  as  
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vasopressors  or  inotropic  agents,  this  is  defined  as  septic  shock  [3].  Severe  sepsis  and  
septic  shock  are  associated  with  higher  mortality  due  to  MODS  and  have  therefore  been  
the  focus  of  most  studies  investigating  the  pathogenesis  of  sepsis.  
The  pathophysiology  of  sepsis  is  quite  complex  and  often  involves  several  organ  
systems  (reviewed  in  [4]).  Patients  may  present  with  disseminated  intravascular  
coagulation  (DIC)  characterized  by  increased  clotting  times,  low  platelet  counts,  and  
compromised  organ  blood  flow.  Endocrine  abnormalities  include  insulin  resistance  
leading  to  hyperglycemia  and  adrenal  insufficiency,  sometimes  requiring  glucocorticoid  
administration.  Cardiovascular  (CV)  dysfunction  is  common;  often  beginning  with  a  
capillary  fluid  leak,  and  after  adequate  fluid  resuscitation,  manifesting  as  a  
hyperdynamic  response  where  cardiac  output  is  high  and  systemic  vascular  resistance  is  
low.  This  progresses  to  a  hypodynamic  state  typical  of  septic  shock  [5].  Acute  renal  
failure,  hepatic  encephalopathy,  adrenal  insufficiency,  and  bacterial  translocation  across  
compromised  gut  epithelium  are  also  complications  of  severe  sepsis.  Therefore,  current  
clinical  management  of  sepsis  provides  some  basic  supportive  care  while  incorporating  
therapies  specific  to  the  affected  organ  systems.  
The  current  standards  of  care  for  treatment  of  patients  with  severe  sepsis  are  
detailed  by  the  2012  Surviving  Sepsis  Campaign  [6]  and  summarized  here.  Immediately  
after  diagnosing  severe  sepsis  or  septic  shock,  appropriate  antimicrobial  coverage,  blood  
cultures,  and  early  goal-­‐‑directed  volume  resuscitation  are  initiated.  If  hypotension  
persists,  further  hemodynamic  support  is  provided  using  vasopressors,  inotropic  agents,  
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and  corticosteroids.  Additional  therapeutic  objectives  may  include  restoring  hemoglobin  
and  platelet  counts,  providing  tight  glucose  control,  mechanically  ventilating  patients  
with  acute  lung  injury  and  acute  respiratory  distress  syndrome  (ARDS),  and  
prophylactically  protecting  against  deep  vein  thrombosis  and  stress  ulcers.  Despite  this  
bundled  care  approach  for  support  of  systemic  organ  function,  sepsis  is  still  associated  
with  high  mortality.    
The  exact  cause  of  mortality  in  severe  sepsis  is  often  not  apparent.    Of  special  
note,  autopsies  of  patients  who  have  died  from  sepsis  have  not  revealed  significant  
histologic  evidence  of  cell  death  that  would  correlate  with  the  degree  of  organ  
dysfunction  [7].  This  implies  that  the  cause  of  death  in  septic  patients  is  much  more  
complex  than  simple  ischemia  with  cellular  necrosis  or  apoptosis.  Therefore,  modern  
research  has  turned  more  attention  to  understanding  broad  molecular  derangements,  
such  as  aberrant  control  of  inflammation  and  mitochondrial  dysfunction,  which  will  be  
described  further  in  this  dissertation.  
  
1.2 TLR4-­‐‑mediated  immune  response  to  bacterial  sepsis  
The  range  of  physiologic  disturbances  seen  in  sepsis  has  long  been  associated  
with  the  specific  underlying  problem  of  an  exaggerated  and  dysregulated  host  
inflammatory  response.  Initiation  of  the  innate  immune  response  occurs  when  immune  
cells,  such  as  macrophages  and  dendritic  cells,  detect  invading  pathogens  via  Toll-­‐‑like  
receptors  (TLRs).  To  date,  10  TLRs  have  been  identified  in  humans  and  12  in  mice,  each  
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with  extracellular  leucine-­‐‑rich  domains  that  recognize  different  lipid,  protein,  and  
nucleic  acid  pathogen-­‐‑associated  molecular  patterns  (PAMPs)  [8].  The  majority  of  TLRs  
are  found  on  the  cell  surface,  with  the  exceptions  being  TLR3,  TLR7,  TLR8,  and  TLR9,  
which  localize  to  intracellular  endosomes  and  lysosomes  and  detect  nucleic  acids  [9].  
TLR4  is  critical  for  the  recognition  of  various  lipopolysaccharides  (LPS)  found  in  Gram-­‐‑
negative  bacteria,  the  pathogen  identified  in  60%  of  culture-­‐‑positive  sepsis  cases  [10-­‐‑12].  
LPS  is  comprised  of  three  subunits;  Lipid  A,  core  polysaccharide,  and  O  antigen  [13].  
Lipid  A  is  a  highly  conserved  disaccharide  and  is  responsible  for  most  of  the  toxicity  
associated  with  LPS  while  the  polysaccharides  of  the  core  and  O  antigen  confer  
immunogenicity  and  are  specific  to  the  bacterial  subtype.    The  core  polysaccharide  
consists  of  an  inner  core  that  attaches  to  Lipid  A,  and  an  outer  core,  which  is  comprised  
of  common  sugars  such  as  hexose.  Attached  to  the  outer  core  is  the  most  variable  
component  of  LPS,  the  O  antigen,  comprised  of  hydrophobic  glycan  chains.  These  lipid  
chains  enable  LPS  to  complex  with  MD-­‐‑2,  LPS  binding  protein  (LBP)  and  CD14,  thus  
activating  the  TLR4  pathway  [8,  14,  15].  As  summarized  in  Figure  1,  oligomerization  of  
TLR4  enables  the  intracellular  activation  of  the  myeloid  differentiation  factor  88  
(MyD88)-­‐‑  and  TIR  domain-­‐‑containing  adapter  inducing  interferon-­‐‑β  (TRIF)-­‐‑dependent  
pathways  [16-­‐‑18].  This  results  in  the  activation  of  the  nuclear  factor-­‐‑κB  (NF-­‐‑κB)  




Figure  1:  Early  host  immune  response  to  sepsis.  LPS  activation  of  TLR4  signals  through  
MyD88  and  TRIF  to  promote  NF-­‐‑κB  nuclear  translocation  and  thus  facilitate  cytokine  
and  NOS2  expression.  These  responses  lead  to  an  increase  in  ROS/RNS,  which  protect  
the  host  system  against  pathogens  but  also  damage  cellular  components.  
  
The  NF-­‐‑κB  family  of  transcription  factors  includes  5  members  categorized  into  2  
subfamilies  [20].  The  NF-­‐‑κB  subfamily  includes  p105  and  p100,  which  are  the  precursors  
to  the  active  p50  and  p52,  respectively.  These  proteins  do  not  activate  transcription  
unless  they  form  a  heterodimer  with  a  member  of  the  Rel  subfamily,  p65  (Rel-­‐‑A),  Rel-­‐‑B,  
or  c-­‐‑Rel  [21].  Although  all  NF-­‐‑κB  proteins  contain  the  Rel  homology  domain  (RHD)  for  
dimerization  and  DNA  binding,  only  Rel  proteins  contain  a  transactivation  domain  
(THD),  enabling  transcription.  With  the  exception  of  Rel-­‐‑B,  which  only  forms  
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heterodimers  in  vivo,  all  other  subunits  can  form  homo-­‐‑  and  heterodimers,  allowing  for  
wide  diversity  in  DNA  binding  specificity,  protein  recruitment  at  target  promoters,  and  
degree  of  transcriptional  activity  [22].  In  order  to  prevent  unwanted  NF-­‐‑κB  activity,  this  
transcription  factor  is  sequestered  in  the  cytoplasm  by  the  inhibitor  of  kappa  B  (IκB)  
family  of  proteins.  Notably,  p50:p65  (Rel-­‐‑A)  is  the  major  heterodimer  formed  in  most  
cells  and  is  preferentially  retained  in  the  cytoplasm  by  IκBα  [23].  Activation  of  the  TLR  
pathway  leads  to  phosphorylation  and  degradation  of  IκB,  enabling  NF-­‐‑κB  to  
translocate  into  the  nucleus  where  it  enables  transcription  of  cytokines  such  as  tumor  
necrosis  factor-­‐‑α  (TNF-­‐‑α),  interleukin-­‐‑6  (IL-­‐‑6),  and  IL-­‐‑1β  [24,  25].  Additionally,  NF-­‐‑κB  
promotes  transcription  of  the  inducible  nitric  oxide  synthase  (NOS2),  which  
enzymatically  converts  L-­‐‑arginine  into  the  gaseous  free  radical,  nitric  oxide  (NO).  Three  
isoforms  of  NOS  exist;  neuronal  NOS1,  inducible  NOS2,  and  endothelial  NOS3  [26].    
NOS1  and  NOS3  are  constitutively  expressed  and  depend  greatly  on  calcium  
concentrations  in  the  cell.  Conversely,  the  calcium-­‐‑independent  NOS2  is  induced  by  
inflammatory  stimuli,  largely  via  NF-­‐‑κB-­‐‑mediated  transcription,  and  generates  much  
greater  quantities  of  NO.  Therefore,  greater  fluxes  of  NO  are  observed  during  infection,  
allowing  for  more  effective  pathogen  clearance  but  also  more  concurrent  cellular  
damage.  
In  addition  to  direct  toxicity  from  NO,  cytokines  and  NO  also  promote  the  
production  of  reactive  oxygen  and  nitrogen  species  (ROS/RNS)  [27].  These  free  radicals  
are  derived  from  O2  and/or  NO  in  reactions  that  will  be  detailed  later  in  the  chapter.  
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Under  normal  situations,  ROS/RNS  are  limited  by  cellular  antioxidant  defenses  but  
when  these  enzymes  are  overwhelmed,  cell  death  and  organ  dysfunction  ensue.    
A  great  deal  of  research  has  been  undertaken  in  the  last  30  years  to  understand  
the  effect  of  the  immune  response  on  the  outcome  of  sepsis  in  animals  and  humans  
(reviewed  in  [28,  29]).  Experimentally,  suppression  of  the  cytokine  response  has  been  
evaluated  in  a  wide  range  of  mouse  models  of  endotoxemia  and  sepsis.  TNF-­‐‑α  and  IL-­‐‑1β  
blockade  improves  survival  in  murine  endotoxemia  [30,  31].  Additionally,  mice  deficient  
in  the  anti-­‐‑inflammatory  cytokine,  IL-­‐‑10,  died  earlier  in  a  model  of  sepsis  produced  by  
cecal  ligation  and  puncture  (CLP)  [32].  The  time  before  which  these  animals  could  be  
rescued  by  surgically  removing  the  necrotic  bowel  was  significantly  reduced,  suggesting  
that  inflammation  accelerates  the  progression  of  disease  and  hastens  the  onset  of  
irreversible  sepsis.  Conversely,  delayed  neutralization  of  IL-­‐‑10  just  12  hours  after  CLP  
sepsis  improved  survival  [33].  Valuable  information  has  also  been  obtained  from  
knockout  and  transgenic  mice.  For  example,  TLR4-­‐‑/-­‐‑  and  C3H/HeJ  mice  with  defective  
TLR4  signaling  are  resistant  to  lethal  LPS  and  protected  from  mitochondrial  
dysfunction,  cardiomyocyte  impairment,  and  LPS-­‐‑induced  shock  [34-­‐‑36].  However,  
these  mice  are  more  susceptible  to  live  Gram-­‐‑negative  infection  due  to  their  inability  to  
clear  the  invading  pathogens  [37].  This  suggests  that  the  exaggerated  immune  response  
in  sepsis  does  contribute  significantly  to  cellular  damage,  but  is  needed  for  bacterial  
clearance  and  host  protection,  especially  in  early  stages  of  the  infection.  
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In  a  similar  manner,  clinical  trials  attempting  to  suppress  the  immune  response  
in  severely  septic  patients  have  also  been  unsuccessful  [38,  39].  Studies  have  employed  
anti-­‐‑endotoxin  antibodies  [40],  TNF-­‐‑α  inhibitors  [41,  42],  and  IL-­‐‑1  receptor  antagonists  
[43]  to  block  host  inflammatory  responses  but  these  treatments  were  ineffective  or  more  
detrimental  than  standard  supportive  care.  Efforts  to  enhance  the  immune  response  did  
not  improve  overall  survival  either,  although  length  of  hospital  stay  was  shorter  in  one  
small  trial  [44,  45].  The  monocyte  activator,  interferon-­‐‑γ  did  promote  the  recovery  of  
macrophage  function  and  improve  survival  in  a  pilot  trial  of  nine  patients  [46],  but  not  
in  a  larger  trial  with  burn  and  trauma  patients  [47,  48].  Collectively,  these  trials  highlight  
the  complexity  of  the  immune  phenotypes  in  sepsis;  the  balance  between  host  pro-­‐‑  and  
anti-­‐‑inflammatory  responses  is  most  important  for  determining  outcome.  Patient  
responses  are  heterogeneous,  beginning  with  a  hyperimmune  response  and  shifting  to  a  
state  of  “immunoparalysis”  [49,  50],  which  may  demand  a  more  stratified  approach  to  
immunotherapy.  Alternatively,  the  sequelae  of  exaggerated  immune  responses  may  be  
better  targeted  for  therapeutic  intervention.  Mitochondria  are  one  such  target  of  immune  
activation  in  sepsis  and  their  damage,  functional  recovery,  and  regulatory  pathways  will  
be  explored  further  in  this  dissertation.    
  
1.3 Mitochondrial  response  to  sepsis  
Mitochondria  are  membrane-­‐‑bound  organelles  present  in  eukaryotic  cells  that  
produce  90-­‐‑95%  of  the  cell’s  adenosine  triphosphate  (ATP)  through  the  process  of  
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oxidative  phosphorylation  (oxphos).  This  bioenergetic  pathway  depends  heavily  on  
mitochondrial  subcellular  organization.  The  outer  mitochondrial  membrane  (OMM)  is  
freely  permeable  to  small  molecules  but  regulates  transport  of  larger  molecules  with  the  
use  of  porins  and  translocase  proteins  embedded  in  the  membrane.  The  inner  
mitochondrial  membrane  (IMM)  is  home  to  the  respiratory  complexes  of  the  
mitochondrial  electron  transport  chain  (ETC).  As  electrons  are  generated  by  the  citric  
acid  (TCA)  cycle  in  the  matrix,  an  electrochemical  proton  gradient  is  established  across  
the  IMM.  These  protons  accumulate  in  the  intermembrane  space  between  the  OMM  and  
the  IMM  and  ultimately  power  the  mechanical  rotation  of  the  ATP  synthase  (complex  V)  
enzyme,  producing  ATP.      
During  oxphos,  electrons  are  removed  from  O2  as  it  is  completely  reduced  to  
H2O.  However,  incomplete  reduction  of  O2  also  occurs,  thus  generating  superoxide  (O2–),  
hydrogen  peroxide  (H2O2),  hydroxyl  ion  (OH–),  and  hydroxyl  radical  (•OH).  Under  
normal  circumstances,  these  reactive  species  are  neutralized  by  antioxidant  enzymes  like  
superoxide  dismutase  (SOD)  and  glutathione  peroxidase.  However,  the  inflammatory  
milieu  in  sepsis  functionally  impairs  ETC  complexes  and  exacerbates  reactive  species  




1.3.1 Sepsis-­‐‑induced  mitochondrial  dysfunction  
The  concept  of  bioenergetic  failure  from  mitochondrial  dysfunction  in  sepsis  was  
introduced  40  years  ago  and  has  been  used  by  some  investigators  to  explain  certain  
aspects  of  septic  shock  symptomatology  [51,  52].  Originally,  MODS  was  thought  to  occur  
secondary  to  tissue  hypoxia  but  with  the  introduction  of  better  pO2  sensors,  it  became  
evident  that  tissue  perfusion  and  oxygenation  are  adequate  and  often  supranormal  
during  sepsis  [53].  Although  tissues  are  able  to  extract  sufficient  oxygen,  the  ability  of  
cells,  and  specifically  mitochondria,  to  adequately  utilize  this  oxygen  is  impaired  [54].  
This  phenomenon,  eventually  termed  ‘cytopathic  hypoxia’,  may  result  from  direct  
inhibition  of  mitochondrial  complexes,  increased  pyruvate  accumulation  &  lactic  
acidosis,  mitochondrial  uncoupling,  and/or  depletion  of  factors  needed  for  oxidative  
phosphorylation  (i.e.  NAD+/NADH)  [54,  55].  This  mitochondrial  dysfunction  results  in  a  
decrease  in  state  3  respiration  and  an  increase  in  state  4  respiration,  which  subsequently  
increases  O2-­‐‑  and  H2O2  production  [51].  The  increase  in  free  radical  production  further  
impairs  mitochondrial  function  by  decreasing  mitochondrial  DNA  (mtDNA)  content,  
promoting  a  3.8  kb  mtDNA  deletion,  and  attenuating  mitochondrial  gene  expression  
[56].    
  
1.3.2 Mitochondrial  biogenesis  
As  mitochondria  age,  are  damaged,  or  respond  to  an  increased  energy  demand,  
the  cell  will  attempt  to  enhance  is  respiratory  function  by  promoting  mitochondrial  
quality  control  (QC).    This  includes  mitochondrial  autophagy  (mitophagy)  and  
  11  
mitochondrial  biogenesis.  Mitophagy  involves  the  sequestration  and  degradation  of  
damaged  mitochondria  and  mitochondrial  biogenesis  is  the  process  by  which  new  
mitochondria  are  formed.      Nisoli  further  defined  mitochondrial  biogenesis  as  the  ability  
to  increase  oxidative  phosphorylation  and  ATP  production  to  meet  energy  demands,  
increase  synthesis  of  new  organelle  components  which  are  integrated  into  the  existing  
mitochondria,  and  import  nuclear  transcribed  proteins  into  the  mitochondria  that  are  
needed  for  appropriate  metabolic  function  [57].  Mitochondrial  biogenesis  is  activated  by  
cellular  stress  or  damage  and  requires  the  interplay  of  both  mitochondrial  and  nuclear  
genes.  The  mitochondrial  genome  encodes  37  genes:  13  genes  for  ETC  subunits,  22  tRNA  
genes,  and  2  rRNA  genes.    Therefore,  most  of  the  hundreds  to  thousands  of  proteins  that  
are  required  for  mitochondrial  function  are  encoded  by  nuclear  DNA  and  must  be  
imported  into  the  mitochondria.    
In  sepsis,  the  goal  of  mitochondrial  biogenesis  is  to  restore  mitochondrial  mass  
and  repair  mtDNA  damaged  by  inflammation.  Damaged  mitochondria  send  retrograde  
signals  to  the  nucleus,  increasing  the  expression  of  nuclear  factors  involved  in  
mitochondrial  biogenesis  [58-­‐‑60]  (Figure  2).  The  family  of  peroxisome  proliferator-­‐‑
activated  receptor  gamma  co-­‐‑activator  (PGC)  proteins  is  a  group  of  three  co-­‐‑activators  
that  regulate  genes  involved  in  fatty  acid  oxidation,  oxidative  phosphorylation,  and  
mitochondrial  biogenesis  [61,  62].  This  family  consists  of  PGC-­‐‑1α,  PGC-­‐‑1β,  and  PGC-­‐‑1  
related  coactivator  (PRC)  [61,  63,  64].  They  all  lack  known  intrinsic  enzymatic  activity,  
but  instead  function  as  a  scaffold  for  other  proteins  that  remodel  chromatin  for  
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transcription  factor  binding  [62].  Nuclear  respiratory  factors-­‐‑1  and  2  (NRF-­‐‑1  and  NRF-­‐‑2)  
are  transcription  factors  that  drive  expression  of  genes  involved  in  mitochondrial  
respiration,  mtDNA  transcription  and  replication,  heme  biosynthesis,  and  protein  
importation  [65].  Collectively,  PGC  coactivators  and  NRF  transcription  factors  
coordinate  the  bigenomic  activation  of  mitochondrial  biogenesis  by  promoting  nuclear  
transcription  of  mitochondrial  transcription  factors  A  and  B  (Tfam  and  TFB,  
respectively)  and  DNA  polymerase-­‐‑γ  (pol-­‐‑γ)  [58].  While  TFB  is  important  for  
mitochondrial  promoter  recognition,  Tfam  is  crucial  in  mitochondrial  biogenesis  as  it  
facilitates  replication  and  transcription  of  mtDNA  in  mammals  [66].  Binding  of  Tfam,  
TFB,  and  pol-­‐‑γ  to  mtDNA  appropriately  activates  mtDNA  replication  [67].    
  
Figure  2:  Key  nuclear  and  mitochondrial  factors  involved  in  mitochondrial  
biogenesis.  ROS/RNS-­‐‑induced  mitochondrial  damage  signal  to  nucleus  to  increase  
production  of  PPAR-­‐‑γ  coactivators  (PGC)  and  DNA-­‐‑binding  transcription  factors,  
nuclear  respiratory  factors-­‐‑1  and  -­‐‑2  (NRF-­‐‑1,  NRF-­‐‑2).  These  proteins  facilitate  the  
transcription  of  nuclear  genes  that  encode  for  proteins  that  promote  mitochondrial  
transcription  and  replication,  e.g.  mitochondrial  transcription  factors  A  and  B  (Tfam,  




Extensive  work  has  demonstrated  that  mitochondrial  biogenesis  is  required  for  
restoration  of  organ  function  and  host  survival.  PGC-­‐‑1,  NRF-­‐‑1,  NRF-­‐‑2,  and  Tfam  have  
all  been  shown  to  be  important  in  mitochondrial  recovery  and  when  these  key  players  
are  reduced  or  absent,  necrosis  and  organ  dysfunction  prevail  [68,  69].  Importantly,  
Tfam  helps  regulate  mammalian  mtDNA  copy  number,  and  in  mice,  Tfam  disruption  
causes  cytopathy,  embryonic  lethality,  and  diabetes  secondary  to  mtDNA  depletion  and  
loss  of  oxidative  phosphorylation  [70].  Mice  deficient  in  PGC-­‐‑1α  were  not  protected  
from  acute  renal  damage  in  response  to  endotoxemia  [71].  Our  lab  has  further  
demonstrated  that  the  induction  of  mitochondrial  biogenic  factors  is  required  for  
protection  against  live  S.  aureus  sepsis  [72],  S.  aureus  pneumonia  [73],  and  E.  coli  sepsis  
[74].  Subsequently,  greater  emphasis  has  been  placed  on  understanding  how  
mitochondrial  biogenesis  is  activated  and  regulated  so  that  this  protective  process  can  
potentially  be  exploited  for  therapeutic  benefit  in  clinical  sepsis.  
  
1.3.3 Heme  oxygenase-­‐‑1  and  mitochondrial  biogenesis  
Heme  oxygenases  (HO)  are  the  rate-­‐‑limiting  enzymes  in  heme  catabolism.  They  
metabolize  heme  to  biliverdin  with  the  production  of  carbon  monoxide  (CO)  and  iron.    
Similar  to  NOS,  constitutive  and  inducible  isoforms  of  HO  have  been  described;  HO-­‐‑1  is  
induced  during  inflammation  and  oxidative  stress  while  HO-­‐‑2  is  constitutively  active.  
HO-­‐‑1  has  been  known  to  confer  protection  through  anti-­‐‑apoptotic,  anti-­‐‑inflammatory,  
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and  anti-­‐‑tumorigenic  mechanisms,  many  of  which  are  thought  to  be  mediated  by  CO  
[75].  More  recently,  HO-­‐‑1  and  CO  have  been  linked  to  mitochondrial  biogenesis.  In  a  
study  that  subjected  mice  to  CLP  sepsis,  HO-­‐‑1/CO  promoted  PGC-­‐‑1α  expression  and  
reduced  mortality  [76].  Furthermore,  our  lab  has  demonstrated  that  HO-­‐‑1/CO  activates  
mitochondrial  biogenesis  in  the  heart  through  the  H2O2-­‐‑dependent  activation  of  
PI3K/Akt  [77].  Moreover,  we  have  confirmed  that  CO  activates  the  mitochondrial  
biogenic  pathway  in  human  skeletal  muscle  [78]  and,  in  mice,  protects  against  
doxorubicin  cardiotoxicity  [68]  and  live  S.  aureus  sepsis  [72].  Subsequently,  our  lab  
continues  to  study  the  mechanism  for  CO  protection  as  a  potentially  translatable  
therapeutic  option  in  human  sepsis.    
  
1.4 The  role  of  nitric  oxide  in  sepsis  
1.4.1 NO  and  sepsis  pathogenesis  
Large  amounts  of  NO  are  produced  by  NOS2  during  sepsis  at  levels  that  damage  
host  cells  and  organ  function.  Within  the  cardiovascular  system,  NO  overproduction  is  
associated  with  hypotension  and  shock  via  cGMP-­‐‑mediated  vascular  smooth  muscle  cell  
relaxation.  NO  may  also  compromise  myocardial  contractility  and  impair  
cardiomyocyte  survival,  thus  promoting  heart  failure  and  poor  clinical  outcomes  [79-­‐‑81].  
NO  impairs  mitochondrial  activity  by  inhibiting  cytochrome  oxidase  and  ubiqinone,  
causing  an  increase  in  O2-­‐‑  and  H2O2  [82].  When  energy  supplies  are  low,  the  reduction  in  
oxidative  metabolism  may  be  beneficial;  mitochondrial  QC  mechanisms  have  more  time  
  15  
to  repair  mtDNA  damage  and  restore  mitochondrial  function.  However,  when  NO  
combines  with  excess  O2-­‐‑  or  H2O2,  peroxynitrite  (ONOO-­‐‑)  is  formed,  which  in  an  acid  
milieu,  decomposes  to  NO2  and  hydroxyl  radicals  that  damage  DNA  and  protein  
through  nitration  and/or  oxidation.  This  especially  occurs  within  the  mitochondria  
where  mtDNA  is  in  closest  proximity  to  ROS/RNS  generation  and  associated  with  very  
few  protective  DNA  binding  proteins  [56,  83].    
Although  NO  is  clearly  involved  in  the  pathogenesis  of  cellular  dysfunction  in  
sepsis,  attempts  to  inhibit  NO  production  have  not  proven  therapeutically  beneficial  in  
humans.  For  example,  studies  using  non-­‐‑specific  NOS  inhibitors  were  terminated  
during  Phase  II  and  Phase  III  clinical  trials  because  of  increased  mortality[84-­‐‑86].    
Therefore,  the  protection  afforded  by  NOS2  likely  reflects  balanced  NO  production  that  
activates  pro-­‐‑survival  responses  with  minimal  overt  NO  toxicity,  inflammation,  and  cell  
damage.    
1.4.2 NO  and  cellular  protection  
Based  on  the  failed  attempts  to  inhibit  NOS2  in  sepsis  patients,  greater  emphasis  
has  been  placed  on  studies  exploring  the  protective  effects  of  NO.  Physiologically,  NO  is  
necessary  for  vascular  patency  and  indispensible  for  vascular  responsiveness  to  
vasoactive  drugs.  Although  some  post-­‐‑translational  S-­‐‑nitrosylation  of  nucleic  acids,  
lipids,  and  proteins  may  be  undesirable,  many  modifications  are  necessary  for  normal  or  
enhanced  protein  function.  For  example,  S-­‐‑nitrosylation  of  caspase-­‐‑8  in  rat  hepatocytes  
protects  against  TNF-­‐‑α-­‐‑mediated  apoptosis  [87]  and  deletion  of  NOS2  exacerbates  
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apoptosis  of  cardiomyocytes  and  hepatocytes  [88,  89].  NO  has  also  been  shown  to  
protect  mitochondria  by  both  maintaining  membrane  potential  and  promoting  
biogenesis  [90,  91].  Specifically  NOS1  and  NOS3  activate  guanylate  cyclase  in  neurons  
and  adipocytes,  respectively,  thereby  facilitating  cGMP-­‐‑dependent  PGC-­‐‑1α  expression  
[57,  92-­‐‑94].  No  comparable  role  for  NOS2  had  been  identified  prior  to  the  work  
presented  in  this  dissertation,  but  here  I  hypothesized  that  NOS2  is  necessary  for  cell  
survival,  in  part,  by  optimizing  mitochondrial  biogenesis.    
1.4.3 Transcriptional  regulators  of  NOS2  expression  
Despite  confirmed  NO-­‐‑mediated  pathology  in  sepsis,  NOS2  is  necessary  for  
survival  in  animal  and  human  studies.  This  confirms  that  balanced  production  of  NO  is  
required  for  optimal  host  survival  (Figure  3).  Insufficient  NO  production  compromises  
pathogen  clearance,  vascular  hemodynamics,  and  mitochondrial  regulation  while  excess  
NO  causes  cellular  dysfunction  and  shock.  The  most  regulated  step  in  inducible  NO  
production  occurs  at  the  mRNA  level  so  transcriptional  control  has  been  a  major  
research  interest  for  diseases  characterized  by  high  NOS2  expression.    
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Figure  3:  The  balance  between  Nos2  transcriptional  activation  and  repression.  The  
transcriptional  regulation  of  Nos2  is  important  because  balanced  production  of  NO  is  
critical  for  preventing  detrimental  effects  on  normal  circulatory  and  cellular  physiology.  
  
The  Nos2  gene  is  transcriptionally  silent  in  unstimulated  cells,  but  during  Gram-­‐‑
negative  infections,  cytokines  and  LPS  synergistically  optimize  transcription  of  the  gene.  
While  LPS  activation  of  the  TLR4  pathway  increases  nuclear  NF-­‐‑κB,  cytokines  such  as  
TNF-­‐‑α,  IFN-­‐‑γ,  and  IL-­‐‑1β  are  needed  for  the  recruitment  of  additional  transcription  
factors  to  the  Nos2  gene  promoter  [95].  IFN-­‐‑γ  is  the  most  potent  co-­‐‑activator  of  Nos2  in  
LPS-­‐‑treated  murine  macrophages  [96],  perhaps  because  of  the  ability  of  IFNs  to  
upregulate  IFN-­‐‑regulatory  factor  1  (IRF-­‐‑1)  [97,  98]  and  signal  transducer  and  activator  of  
transcription-­‐‑1  (STAT-­‐‑1)  [99].  Activator  protein-­‐‑1  (AP-­‐‑1)  and  cAMP  responsive  element  
binding  protein  (CREB)  also  participate  in  the  transcriptional  expression  of  Nos2  [100].  
These  transcription  factors  collaboratively  promote  mRNA  synthesis,  which  is  quickly  
translated  into  proteins  that  dimerize  and  associate  with  cofactors,  such  as  heme  and  





Nos2 transcriptional repressors: 
NF- κB  repressing factor, ER-α, PPAR-γ,  
Heme Oxygenase-1 (HO-1) 
Nos2 transcriptional activators: 
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Nos2  transcriptional  repression  is  a  much  more  limited  area  of  research.  Since  
NF-­‐‑kB  is  well  recognized  as  a  necessary  component  for  NOS2  expression,  the  majority  of  
studies  showing  reductions  in  Nos2  transcription  have  involved  interference  in  NF-­‐‑kB  
promoter  binding,  whether  by  preventing  heterodimer  formation,  blocking  DNA  
binding,  or  increasing  cytosolic  IκB  [100-­‐‑102].    Other  potential  repressors  of  Nos2  include  
NF-­‐‑κB  repressing  factor,  estrogen  receptor  (ER)-­‐‑α,  and  peroxisome  proliferator-­‐‑activated  
receptor  (PPAR)-­‐‑γ  but  these  have  not  been  well  characterized  [100].  Of  specific  interest  
here,  reports  have  also  shown  that  HO-­‐‑1  negatively  regulates  NOS2.    Proposed  
mechanisms  include  direct  inhibition  of  the  NOS2  enzyme  by  CO  [103]  and  activation  of  
pathways  that  would  ultimately  block  transcription  [104].  Unfortunately,  the  specific  
changes  in  transcription  factor  recruitment  and  binding  at  the  Nos2  promoter  that  are  
mediated  by  HO-­‐‑1/CO  activity  have  not  been  thoroughly  investigated.    
1.4.4 Cross  talk  between  HO-­‐‑1  and  NOS2  pathways    
NO  and  CO  are  gaseous  modulators  that  are  made  endogenously  and  mediate  
intracellular  signaling  through  their  interaction  with  specific  targets  [105].  These  gases  
share  several  common  characteristics.  Both  gases  act  as  second  messengers  in  cellular  
processes  such  as  smooth  muscle  relaxation,  vascular  responsiveness,  and  anti-­‐‑
inflammation  [106].  However,  when  levels  are  too  high,  both  contribute  to  disease  
pathology.  NO  and  CO  have  been  shown  to  competitively  inhibit  O2  binding  to  
cytochrome  oxidase,  thus  increasing  ROS  production  within  the  mitochondria  [107,  108].    
In  response  to  Gram-­‐‑negative  challenge,  HO-­‐‑1  and  NOS2  are  highly  inducible  and  yield  
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high  levels  of  their  respective  gases.  Subsequently,  these  similarities  have  prompted  
investigations  focused  on  characterizing  the  interaction  between  the  HO-­‐‑1/CO  and  
NOS2/NO  pathways.    
In  several  inflammatory  models,  NO/NOS2  has  been  shown  to  further  enhance  
HO-­‐‑1  activity  and  CO  production.  This  relationship  has  been  confirmed  in  
cardiomyocytes,  adrenal  gland,  vascular  smooth  muscle  cells  (SMC),  hepatocytes,  and  
Kupffer  cells  [109-­‐‑113].    Various  mechanisms  have  been  described  and  include  induction  
of  HO-­‐‑1  by  cGMP  signaling  and  recruitment  of  transcription  factors  to  the  Hmox1  
promoter  (i.e.  NF-­‐‑κB  p50/p65  and  nuclear  Nrf2)  [109,  111,  112].  As  a  result,  some  of  the  
protective  effects  of  NOS2  may  result  from  HO-­‐‑1  downstream  signaling.  
Conversely,  several  studies  suggest  that  HO-­‐‑1  inhibits  NOS2  expression  and/or  
activity.  Experimental  designs  have  included  rats  subject  to  ischemia/reperfusion  injury  
or  endotoxemia  [114,  115],  LPS  treated  macrophages  [103,  116,  117],  and  IL-­‐‑1β-­‐‑treated  
astrocytes  [104].  Several  mechanisms  for  NOS2  suppression  have  been  suggested.  HO-­‐‑1  
can  inhibit  NOS2  activity  by  reducing  the  availability  of  heme,  a  cofactor  that  is  required  
for  the  dimerization  and  activity  of  NOS2,  or  the  direct  binding  of  CO  to  the  enzyme  
[103,  118].  CO  can  also  repress  NOS2  at  the  transcriptional  level,  as  seen  in  reports  
linking  HO-­‐‑1/CO  to  reduced  p38  MAPK  signaling,  deactivation  of  STAT-­‐‑1  or  STAT-­‐‑3  
[114],  or  enhanced  IL-­‐‑10  production  [114,  119-­‐‑121].  Otterbein,  et  al.  demonstrated  that  
CO  increased  IL-­‐‑10  levels,  thereby  reducing  serum  TNF-­‐‑α  levels  in  LPS-­‐‑treated  mice  and  
RAW264.7  macrophages  [119].    Most  recently,  our  lab  demonstrated  that  HO-­‐‑1/CO  has  
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this  same  effect  in  a  model  of  murine  E.  coli  sepsis  [120]  but  no  direct  relationship  
between  HO-­‐‑1,  IL-­‐‑10,  and  NOS2  has  been  confirmed.  Much  less  is  known  about  the  
ability  of  other  HO-­‐‑1  metabolites  to  reduce  NOS2  expression  or  activity  but  a  few  
studies  have  associated  hyperbilirubinemia  with  NOS2  inhibition  in  rat  models  [122-­‐‑
124].      
Unfortunately,  most  studies  showing  NOS2  inhibition  by  HO-­‐‑1  are  inadequate  
because  they  often  report  associated  changes  in  transcriptional  pathways  that  were  
never  proven  to  directly  reduce  Nos2  activation.  This  lack  of  a  definite  link  between  the  
transcriptional  network  and  NOS2  promoter  activity  must  be  addressed  before  we  can  
expect  to  develop  meaningful  clinical  applications.  Therefore,  the  Aim  of  the  second  part  
of  this  thesis  was  to  1)  demonstrate  that  HO-­‐‑1  suppresses  Nos2  gene  induction  during  
Gram-­‐‑negative  challenge  and  2)  better  characterize  the  mechanism  for  this  relationship  
in  liver  cells.  Due  to  significant  limitations  of  the  model  chosen  for  this  study,  actual  
transcriptional  regulatory  mechanisms  were  not  assessed.  However,  this  work  suggests  
that  future  evaluation  of  NOS2  transcriptional  control  should  focus  more  on  the  
recruitment  of  specific  transcription  factors,  such  as  NF-­‐‑κB,  STAT-­‐‑1,  STAT-­‐‑3,  and  CREB,  
to  the  Nos2  promoter.  Ideally,  this  knowledge  would  enhance  our  ability  to  
therapeutically  target  the  HO-­‐‑1/CO  pathway  in  inflammatory  conditions  and  thus  
simultaneously  attenuate  inflammation  and  recruit  mitochondrial  repair  mechanisms.    
1.5 Mouse  models  of  sepsis  
Animal  models  have  been  used  for  decades  to  recapitulate  the  systemic  findings  
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in  sepsis.  Due  to  the  complex  nature  of  human  sepsis,  finding  an  appropriate  in  vivo  
model  has  been  challenging.  Most  studies  have  been  conducted  in  mice  and  rats  because  
of  their  small  size,  low  cost,  and  availability  of  genetic  variants.  However,  these  models  
of  sepsis  are  limited  by  the  difficulties  in  monitoring  cardiopulmonary  parameters  and  
recapitulating  the  dynamic  immunologic  and  physiologic  responses  that  occur  in  septic  
patients.    Furthermore,  new  data  shows  that  although  the  genetic  signatures  seen  in  
burn,  endotoxic,  and  trauma  patients  are  very  similar,  they  correlate  poorly  with  the  
genetic  profile  of  their  relevant  mouse  models  [125].  Animal  models  of  clinical  sepsis  
must  therefore  be  interpreted  cautiously.  Meaningful  information  has  been  obtained  
from  animal  studies,  but  data  over-­‐‑interpretation  may  account  for  the  failure  of  novel  
clinical  approaches  that  showed  promise  in  preclinical  studies  [126,  127].  Several  
commonly  used  mouse  models  are  reviewed  below.  
“Endotoxemia”  Injection  Models:  Large  doses  of  LPS  injected  in  the  peritoneum  
or  tail  vein  of  mice  were  used  in  original  models  of  sepsis.  To  produce  cytokine  
responses  similar  to  humans,  mice  must  be  given  250  times  higher  doses  of  LPS  [128].  
Challenged  animals  respond  by  inducing  a  massive,  transient  production  of  cytokines  
peaking  between  1.5-­‐‑4.5  hours  [129].  LPS  has  also  been  administered  to  healthy  patients  
who  mount  a  systemic  response  that  is  similar  to  that  of  patients  with  bacterial  sepsis.  
However,  translation  of  therapies  derived  from  animal  endotoxemia  models  to  clinical  
trials  for  human  sepsis  has  been  unsuccessful.  This  is  largely  due  to  significant  
differences  in  the  physiological  response  in  mice  versus  humans.  For  instance,  the  
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cytokine  response  in  endotoxic  mice  peaks  earlier  and  to  a  greater  degree  than  in  
patients  with  sepsis  [130].  Furthermore,  endotoxic  mice  elicit  a  hypodynamic,  low  
cardiac  output  CV  response  without  the  initial  hyperdynamic  state  observed  in  human  
sepsis.  This  high  output  CV  state  may  be  observed  if  animals  are  given  LPS  infusions  
and  fluid  resuscitation  but  generally,  endotoxic  models  are  characterized  by  a  much  
faster  disease  progression  than  what  is  typically  observed  in  human  patients.  
Comparatively,  inoculations  of  heat-­‐‑killed  and  live  bacteria  enable  a  response  that  is  
directed  at  the  whole  microbe  but,  when  given  in  a  single,  high-­‐‑dose,  have  physiologic  
responses  that  mirror  that  of  LPS  injections.    
“Sepsis”  Surgical  Models:  Animal  models  that  require  a  surgical  intervention  are  
currently  considered  the  closest  correlate  to  human  sepsis.  Implantation  of  bacterial  
fibrin  clots  into  the  peritoneum  of  larger  animals  creates  a  sepsis  phenotype  with  a  more  
gradual  disease  progression,  hyper-­‐‑  and  hypodynamic  CV  states,  and  delayed  mortality  
[131,  132].  Our  lab  subsequently  developed  a  mouse  model  of  fibrin  clot  implantation  
that  demonstrates  dose-­‐‑dependent  mortality,  progressive  weight  loss,  decreased  
metabolic  activity,  and  gradual  cytokine  induction  [69].      This  model  correlates  well  to  
single-­‐‑microbe  infections  implicated  in  human  sepsis,  such  as  E.  coli  urosepsis  and  S.  
aureus  pneumonia.  Alternatively,  cecal  ligation  and  puncture  (CLP)  can  be  used  to  
simulate  sepsis  from  intestinal  perforation  or  mixed-­‐‑microbe  infections.  In  this  instance,  
the  cecum  is  tied  off  and  pierced  with  a  needle  to  allow  GI  flora  to  leak  into  the  
peritoneal  cavity  [133,  134].  Cytokine  levels  in  this  surgical  model  are  significantly  lower  
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and  more  sustained  than  the  endotoxin  model.  However,  significant  variability  can  
occur  in  mice  due  to  different  genetic  backgrounds,  sex,  technical  approach,  and  
supportive  care  given  post-­‐‑operatively  [130].  This  model  is  limited  by  the  occurrence  of  
necrotic  bowel  and  abscess  formation,  and  standardization  of  technique  used  by  various  
labs.    
When  evaluating  the  host  response  to  E.  coli,  our  lab  most  frequently  uses  
surgical  fibrin  clot  implantation  and  heat-­‐‑killed  bacteria  injected  IP.  Both  models  are  
used  in  this  dissertation  with  the  bulk  of  data  generated  in  the  heat-­‐‑killed  E.  coli  (HkEC)  
peritonitis  model.  Initial  survival  studies  were  conducted  in  the  setting  of  live  E.  coli  
fibrin  clot  peritonitis,  but  HkEC  was  used  for  mechanistic  studies  to  avoid  differences  in  
bacterial  load  in  control  versus  NOS2  and  TLR4-­‐‑deficient  mice.    Furthermore,  
experiments  evaluating  mitochondrial  biogenesis  in  this  dissertation  were  performed  in  
the  heart,  but  later  confirmed  by  my  lab  in  the  liver.  Nos2  transcriptional  regulation  was  
subsequently  evaluated  in  the  liver  since  both  heme  oxygenase-­‐‑1  and  NOS2  show  strong  
induction  in  this  organ.    
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2. NOS2  promotes  mitochondrial  biogenesis  during  E.  coli  
peritonitis  
The  first  Aim  of  this  thesis  project  was  to  define  the  protective  role  of  NOS2  in  a  
model  of  Gram-­‐‑negative  infection  as  it  pertains  specifically  to  mitochondrial  biogenesis  
and  cell  respiration.  Both  NOS1  and  NOS3  isoforms  have  been  shown  to  induce  
mitochondrial  biogenesis  in  neurons  and  adipocytes,  respectively.  Therefore,  this  Aim  
was  based  on  the  hypothesis  that  NOS2  is  indispensible  for  cell  survival  and  organ  
function  in  sepsis  through  mitochondrial  biogenesis.  To  test  this  hypothesis,  several  
endpoints  were  evaluated  in  C56BL/6  wild  type  (Wt),  NOS2−/−,  and  TLR4-­‐‑/-­‐‑  mice  infected  
with  E.  coli.  These  endpoints  included  survival,  mitochondrial  function,  nuclear  
transcription  factors/co-­‐‑activators,  and  mitochondrial  effectors  that  are  critical  for  
mitochondrial  biogenesis  in  cardiac  tissue.  The  survival  study  was  originally  published  
by  HB  Suliman,  A  Babiker,  CM  Withers,  et  al.  in  2010  [135].  All  mitochondrial  biogenesis  
data  using  Wt,  NOS2−/−,  and  TLR4-­‐‑/-­‐‑  mice  was  published  by  CM  Reynolds,  HB  Suliman,  
JW  Hollingsworth,  et  al.  in  2009  [136].    
  
2.1. NOS2  protection  during  E.  coli  fibrin  clot  peritonitis  
To  determine  whether  NOS2  is  necessary  for  survival  in  E.  coli  sepsis,  fibrin  clots  
containing  107  live  E.  coli  were  implanted  surgically  into  the  peritoneal  cavities  of  Wt  
and  NOS2−/−  mice.  Animals  were  monitored  for  one  week  after  which  any  surviving  
mice  were  euthanized.  As  shown  in  Figure  4,  survival  differences  were  observed  as  early  
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as  two  days  with  NOS2−/−  mice  being  more  sensitive  to  live  bacterial  sepsis  (83%  vs  41%  
survival  in  Wt  vs  NOS−/−  mice,  p<0.05).    Only  17%  of  NOS2-­‐‑deficient  mice  survived  
longer  than  4  days.    This  supports  prior  studies  depicting  increased  susceptibility  of  
NOS2−/−  mice  to  live  bacteria  [137].  
  
Figure  4:  Survival  curve  for  E.  coli  fibrin  clot  peritonitis.  Clots  containing  1x107  Alive  
bacteria  were  surgically  implanted  into  the  peritoneum  of  Wt  and  NOS2−/−  mice.  
Survival  reflected  higher  mortality  in  NOS2-­‐‑deficient  animals.  (p<0.05,  n=12  per  group).  
  
Bacteremia  was  assessed  in  both  mouse  strains  by  culturing  blood  taken  from  the  
hearts  of  mice  24  hours  after  surgery.  Blood  cultures  showed  that  while  Wt  mice  were  
effectively  able  to  control  the  bacterial  inoculum,  NOS2−/−  mice  developed  significant  
bacteremia  (Figure  5),  likely  contributing  to  the  lethality  in  knockout  (KO)  mice.  Since  
the  differences  in  bacterial  burden  can  significantly  alter  physiologic  responses  in  NOS2-­‐‑
deficient  mice,  further  mechanistic  studies  were  performed  using  the  sublethal  HkEC  
model  of  peritonitis.  Increasing  doses  of  HkEC  were  administered  to  Wt  and  NOS2-­‐‑/-­‐‑  
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mice  (data  not  shown)  and  a  dose  of  108  CFU  HkEC  was  the  highest  amount  that  could  
be  administered  without  lethality  in  KO  mice.  
  
Figure  5:  Bacterial  burden  in  Wt  and  NOS2-­‐‑/-­‐‑  mice  with  107  CFU  E.  coli  fibrin  clot  
sepsis.  Blood  from  intracardiac  aspiration  24  hours  after  surgery  was  inoculated  on  LB  
agar  plates  and  observed  for  colony  growth  18-­‐‑24  hours  later.  NOS2-­‐‑deficent  mice  
become  bacteremic  while  Wt  mice  mostly  contained  their  infections.  Picture  is  
representative  of  triplicate  experiments.    
  
2.2. Effect  of  NOS2  on  mitochondrial  damage  and  dysfunction  
during  HkEC  peritonitis  
Since  mitochondria  are  damaged  by  cytokines  and  NO  produced  during  sepsis,  
the  pro-­‐‑inflammatory  response  to  sub-­‐‑lethal  HkEC  IP  was  evaluated  in  NOS2−/−  and  
TLR4−/−  mice  using  quantitative  real-­‐‑time  RT-­‐‑PCR  (qRT-­‐‑PCR).  The  production  of  pro-­‐‑
inflammatory  IL-­‐‑1β,  IL-­‐‑6,  TNF-­‐‑α,  and  leukocyte  adhesion  molecule  ICAM-­‐‑1  increased  
rapidly  in  the  hearts  of  Wt  mice,  dissipating  by  72  hours  (Figure  6).  In  contrast,  NOS2-­‐‑
deficiency  attenuated  and  delayed  cytokine  expression,  indicating  that  knockout  mice  
are  less  responsive  to  Gram-­‐‑negative  challenge.  As  expected,  TLR4−/−  mice  mounted  no  
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early  pro-­‐‑inflammatory  response  to  HkEC  but  did  generate  a  late  TNF-­‐‑α  response,  
suggesting  delayed  activation  of  an  alternative  inflammatory  pathway.    
  
Figure  6:  Selected  blunting  of  cytokine  responses  after  HkEC  in  TLR4-­‐‑/-­‐‑  and  NOS2-­‐‑/-­‐‑  
relative  to  Wt  mice.  Hearts  of  Wt,  TLR4-­‐‑/-­‐‑,  and  NOS2-­‐‑/-­‐‑  mice  collected  after  HkEC.    
Quantification  of  A:  IL-­‐‑1β,  B:  IL-­‐‑6,  C:  ICAM-­‐‑1,  and  D:  TNF-­‐‑α  mRNA  expression  in  all  
three  strains  by  qRT-­‐‑PCR.    †p<0.05  versus  0h  Wt.    *p<0.05  vs  0h  Wt  and  other  strains  at  
same  time.  (n=3-­‐‑5  mice  per  point)    
  
To  quantify  mitochondrial  damage,  cytochrome  b  was  amplified  from  isolated  
mitochondria  as  an  approximation  of  mtDNA  copy  number.  Copy  number  fell  
significantly  in  both  Wt  and  NOS2-­‐‑deficient  mice  24  hours  after  HkEC  peritonitis  but  
only  Wt  animals  were  able  to  fully  recover  by  72  hours  (Figure  7A).  Consistent  with  their  
limited  cytokine  response,  TLR4-­‐‑deficient  mice  demonstrated  no  significant  
mitochondrial  damage  until  72  hours,  suggesting  that  late  stage  mtDNA  damage  is  
TLR4-­‐‑independent.  The  mtDNA  damage  observed  in  Wt  and  NOS2−/−  mice  did  not,  
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however,  completely  correlate  with  mitochondrial  function.  After  a  significant  decline  in  
State  3  respiration,  both  Wt  and  NOS2-­‐‑deficient  mice  regained  full  mitochondrial  
function  (Figure  7B).  NOS2−/−  mice  most  likely  recovered  72h  respiratory  capacity  in  spite  
of  unresolved  mtDNA  damage  because  of  a  compensatory  increase  in  metabolic  activity  
of  intact  mitochondria.  However,  it  is  expected  that  a  second  insult  would  be  
overwhelming  for  these  KO  animals  and  result  in  persistent  mitochondrial  dysfunction  
and  increased  mortality.  
  
Figure  7:  Analysis  of  mtDNA  and  mitochondrial  function  after  HkEC.  Hearts  from  Wt,  
TLR4−/−,  and  NOS2−/−  mice  after  108  HkEC.  A:  MtDNA  copy  number,  as  determined  by  
qRT-­‐‑PCR  of  cytochrome  b,  plotted  logarithmically.  B:  State  3  respiration  in  isolated  
mitochondria  of  Wt  and  NOS2-­‐‑deficient  mice.  Outer  mitochondrial  membrane  protein,  
porin,  shown  as  a  loading  control.  While  Wt  and  NOS2-­‐‑/-­‐‑  mice  both  recovered  
respiratory  function  after  peritonitis,  only  Wt  were  able  to  repair  mtDNA  damage.  
†p<0.05  vs  0  h  Wt  or  NOS2−/−,  respectively.  (n=2-­‐‑5  mice  per  point)  
  
2.3. Mitochondrial  biogenesis  in  Wt,  NOS2-­‐‑/-­‐‑,  and  TLR4-­‐‑/-­‐‑  mice  
In  response  to  mtDNA  damage,  cells  must  increase  the  production  of  
transcriptosomal  proteins  that  work  within  mitochondria.  Two  of  the  key  regulatory  
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proteins  involved  in  mitochondrial  biogenesis,  Tfam  and  pol-­‐‑γ,  were  therefore  measured  
in  mitochondrial  preparations  by  Western  blot.  HkEC  induced  the  accumulation  of  both  
Tfam  and  Pol-­‐‑γ  by  24  hours  in  Wt  mice  but  not  in  TLR4  and  NOS2  KO  mice  (Figure  8).  
The  expression  of  these  transcriptosomal  proteins  preceded  the  recovery  of  mtDNA  
copy  number  in  Wt  mice;  subsequently,  the  reduced  accumulation  of  these  
mitochondrial  factors  provides  an  explanation  for  why  NOS2−/−  mice  are  unable  to  repair  
their  damaged  mtDNA.  
  
Figure  8:  Expression  of  mitochondrial  proteins  involved  in  biogenesis.  A:  Western  blot  
of  mitochondrial  Tfam  and  Pol-­‐‑γ  in  cardiac  tissue  from  HkEC-­‐‑treated  Wt,  TLR4-­‐‑,  and  
NOS2-­‐‑deficient  mice.  Porin  shown  as  a  loading  control.  B:  Densitometry  of  westerns  
represented  graphically.  Mitochondrial  accumulation  of  these  proteins  is  impaired  in  
KO  mice.  *p<0.05  vs  time  0  and  the  other  two  strains.  (n=2  per  group)  
  
NRF-­‐‑1  transcription  factor  and  the  PGC-­‐‑1α  co-­‐‑activator  coordinate  the  bi-­‐‑
genomic  transcription  that  occurs  in  mitochondrial  biogenesis  by  facilitating  expression  
of  mitochondrial  factors  like  Tfam  and  Pol-­‐‑γ.  Evaluation  of  these  upstream  regulators  
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showed  that  NRF-­‐‑1  and  PGC-­‐‑1α  increased  24  hours  after  HkEC  and  declined  by  72  hours  
in  Wt  mice  (Figure  9).  Conversely,  the  accumulation  of  these  factors  is  reduced  in  both  
knockout  mouse  strains.  Although  data  is  not  shown  here,  activity  of  Akt  and  AMP  
kinase  that  normally  increases  six  hours  after  HkEC  in  Wt  mice  is  blunted  in  KO  mice.  
These  pro-­‐‑survival  kinases  are  known  to  activate  NRF-­‐‑1  and  PGC-­‐‑1α  [68,  138].  
Therefore,  this  data  suggests  that  in  the  heart,  NOS2  is  required  for  the  repair  of  mtDNA  
through  mitochondrial  biogenesis  by  enabling  pro-­‐‑survival  kinase  activation  and  
subsequent  protein  expression.    
  
Figure  9:  Expression  of  nuclear  proteins  involved  in  mitochondrial  biogenesis.  A:  
Western  blot  of  NRF-­‐‑1  and  PGC-­‐‑1α  in  cardiac  tissue  from  Wt,  TLR4-­‐‑,  and  NOS2-­‐‑
deficient  mice  after  HkEC  administration.  Tubulin  shown  as  a  loading  control.  B:  
Densitometry  of  westerns  represented  graphically.  Nuclear  accumulation  of  these  




2.4. Localization  of  NOS2  and  TLR4  expression  following  HkEC  
exposure  
NOS2  is  expressed  in  immune  cells  such  as  macrophages  but  also  localizes  to  
other  cell  types  including  cardiac  myocytes  and  hepatocytes  [139-­‐‑141].  To  localize  both  
TLR4  and  NOS2  expression  in  cardiac  tissue  and  evaluate  its  association  with  loss  of  
mitochondrial  mass,  transgenic  mice  containing  a  COX8  mitochondrial-­‐‑tagged  green  
fluorescent  protein  (GFP)  reporter  were  injected  intraperitoneally  with  HkEC.  Cardiac  
sections  from  these  animals  were  stained  using  antibodies  against  TLR4  or  NOS2  (red  
fluorescence).  Mitochondrial  mass  was  tracked  with  green  fluorescence.  Fluorescence  
microscopy  demonstrated  that  HkEC  promoted  a  loss  of  cardiomyocyte  mitochondrial  
mass  at  six  and  24  hours,  which  recovered  by  72  hours  (Figure  10A  and  10B,  a-­‐‑e).  Since  
the  COX8  mitochondrial  leader  sequence  (MLS)  attached  to  the  GFP  protein  localizes  
GFP  to  the  mitochondria,  the  loss  of  GFP  in  six-­‐‑24  hours  reflects  mitochondrial  damage  
and  clearance  (mitophagy).    
In  control  hearts,  TLR4  expression  is  seen  at  low  intensity  in  vascular  
endothelium  but  not  within  the  myocardium.  However,  six  hours  after  HkEC,  TLR4  
expression  increases,  localizing  primarily  to  the  plasma  membranes  of  mononuclear  and  
endothelial  cells,  and  progressively  emerging  near  the  sarcolemma  and  in  contiguous  
cardiomyocytes  (concluded  from  higher  magnification  photos)  (Figure  10A,  f-­‐‑j).  The  
presence  of  TLR4,  therefore,  associates  first  with  the  onset  of  mitochondrial  damage  and  
then  recovery  through  mitochondrial  biogenesis,  both  of  which  have  been  identified  as  
TLR4-­‐‑dependent  processes.  
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NOS2  protein  was  also  not  visualized  in  control  hearts  but  evident  six  hours  after  
HkEC  challenge,  primarily  in  the  vascular  wall  and  less  prominently  in  the  sarcoplasm  at  
six,  24,  and  24  hours  (Figure  10B,  f-­‐‑j).  Accordingly,  the  induction  of  NOS2  appears  to  
coincide  with  mitochondrial  damage  and  persist  through  the  initiation  of  mitochondrial  
recovery,  supporting  both  damaging  and  protective  roles  of  NOS2  in  vivo.    
The  findings  presented  in  this  first  Aim  demonstrate  that  NOS2  is  necessary  for  
protection  in  Gram-­‐‑negative  challenge  because  it  optimizes  the  mitochondrial  biogenic  
response  to  mtDNA  damage  in  the  heart.  Even  in  the  absence  of  NOS2,  HkEC  damages  
mitochondria  likely  by  other  TLR4-­‐‑mediated  inflammatory  mediators  such  as  TNF-­‐‑α,  
but  NOS2-­‐‑/-­‐‑  mice  show  a  clear  deficiency  in  their  ability  to  recover  from  this  mtDNA  
damage.  Furthermore,  NOS2  appears  to  participate  in  the  early  activation  of  
mitochondrial  biogenesis.  In  the  liver,  NOS2  is  involved  in  the  phosphorylation  of  
kinases,  Akt  and  AMPK,  quote  possibly  through  activation  of  the  NO/cGMP  pathway  
[142].  In  cardiac  tissue  following  HkEC  peritonitis,  NOS2  is  required  for  S-­‐‑nitrosylation  
of  Hsp60,  a  chaperone  protein  that  aids  in  mitochondrial  importation  [143],  and  
subsequent  association  with  Tfam  [135].  Therefore,  NOS2  supports  mitochondrial  
biogenesis  in  the  heart  and  liver  of  E.  coli  challenged  mice  by  at  least  two  mechanisms:  





Figure  10:  Immunofluorescence  for  COX8,  TLR4,  and  NOS2  in  mitochondrial  reporter  
mice  following  HkEC  exposure.  A:  Formalin-­‐‑fixed,  paraffin-­‐‑embedded  cardiac  tissue  
visualized  for  a-­‐‑e:  COX8  (green  fluorescence),  f-­‐‑j:  TLR4  (red  fluorescence),  and  
superimposed  in  panels  k-­‐‑o.    B:  Formalin-­‐‑fixed,  paraffin-­‐‑embedded  cardiac  tissue  
visualized  for  a-­‐‑e:  COX8  (green  fluorescence),  f-­‐‑j:  NOS2  (red  fluorescence),  and  
superimposed  in  panels  k-­‐‑o.  TLR4  and  NOS2  were  induced  with  mitochondrial  damage  
and  sustained  through  initiation  of  mitochondrial  recovery.       
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3. The  Role  of  HO-­‐‑1  in  Nos2  Transcriptional  Regulation  
during  HkEC  Peritonitis  
The  second  Aim  of  this  research  project  was  to  evaluate  NOS2  expression  in  a  
model  of  Gram-­‐‑negative  peritonitis  when  HO-­‐‑1  enzyme  activity  is  enhanced.  This  
objective  was  based  on  the  hypothesis  that  HO-­‐‑1  dampens  the  immune  response  
through  endogenous  CO  generation  from  heme  metabolism,  in  part  by  specifically  
repressing  Nos2  expression.  To  test  this  hypothesis,  C56BL/6  wild  type  (Wt)  mice  were  
challenged  with  a  sub-­‐‑lethal  dose  of  108  CFU  HkEC  and  the  effect  of  HO-­‐‑1  activation  was  
evaluated  in  the  liver.  The  endpoints  being  measured  included  mRNA  expression  of  
Hmox1,  Nos2,  and  acute  phase  cytokines;  protein  expression  of  NOS2  and  HO-­‐‑1;  and  
availability  of  IκBα  and  NF-­‐‑κB.  A  visual  representation  of  the  experimental  setup  is  
shown  in  Figure  11.  
  
Figure  11:  Experimental  design  for  in  vivo  mouse  HkEC  peritonitis  studies.  Mice  were  
administered  subcutaneous  (SQ)  hemin  8  hours  before  HkEC  or  inhaled  (INH)  CO  4h  
before  and  at  the  time  of  108  HkEC  injection.  Liver  was  harvested  at  indicated  times.  
  35  
3.1. HO-­‐‑1  control  on  NOS2  expression  
In  order  to  evaluate  the  effect  of  HO-­‐‑1  on  NOS2  expression,  the  gene  expression  
profiles  of  both  Nos2  and  Hmox1  were  analyzed  after  injection  of  a  single  dose  of  108  
CFU  HkEC  in  Wt  mice  (Figure  12).  As  expected  for  Gram-­‐‑negative  challenge,  expression  
of  Nos2  in  the  liver  increased  quickly,  with  an  approximate  300x  induction  evident  at  4  
hours  that  quickly  declined  through  24  hours  (Figure  12A).  Hmox1  mRNA  levels  rose  
more  gradually,  steadily  increasing  through  24  hours  (Figure  12B).  For  the  duration  of  
the  in  vivo  work,  changes  in  Nos2  expression  were  evaluated  four  hours  after  HkEC  
exposure.  This  time  was  selected  because  it  corresponded  to  peak  Nos2  mRNA  
expression.  Furthermore,  it  is  feasible  that  transcriptional  control  mechanisms  that  could  
suppress  the  most  acute  and  robust  Nos2  response  would  also  be  effective  at  later,  less  
intense  stages  of  transcriptional  activation.  Unfortunately,  the  high  variability  in  peak  
mRNA  levels  in  animals  harvested  at  this  early  time  point  was  not  initially  considered  
but  became  problematic  in  later  analysis.  
  
Figure  12:  Induction  of  Nos2  and  Hmox1  mRNA  following  HkEC  peritonitis  in  mice.  
Wt  mice  were  injected  with  108  HkEC  IP.  A:  Nos2  and  B:  Hmox1  mRNA  expression  in  the  
liver  using  qRT-­‐‑PCR.  Values  plotted  as  fold  change  vs  0  hr  controls.  *p<0.05  vs  0  hr  
controls.  (n=3-­‐‑7  mice  per  time  point)  
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In  this  mouse  model  of  HkEC  peritonitis,  HO-­‐‑1  activity  was  enhanced  by  
pretreating  the  mice  with  hemin  or  CO.  Hemin  is  a  substrate  for  the  HO-­‐‑1  enzyme  and  a  
potent  inducer  of  the  gene,  thus  stimulating  enzyme  activity  and  the  endogenous  
production  of  CO,  biliverdin,  and  iron.  Exogenous  CO  acts  downstream  of  the  HO-­‐‑1  
enzyme  but  also  exerts  positive  feedback  on  protein  expression.  The  increase  in  HO-­‐‑1  
activity  over  HkEC  alone  in  the  liver  was  confirmed  when  animals  were  pretreated  with  
subcutaneous  (SQ)  hemin  (50  µmol/kg)  (Figure  13).  Although  a  single  4h  pretreatment  of  
inhaled  (INH)  CO  (250  ppm  x  1  hour)  before  HkEC  did  not  significantly  increase  HO-­‐‑1  
activity,  two  doses  of  CO  (2xCO)  did  enhance  4h  enzyme  activity  over  HkEC  alone.  
Therefore,  subsequent  animal  experiments  used  hemin  and  2xCO  pretreatments  for  HO-­‐‑
1  activation.  In  an  attempt  to  suppress  HO-­‐‑1  activity,  zinc  protoporphyrin  (ZnPP,  3  
mg/kg)  was  given  four  hours  before  HkEC  exposure  but  these  mice  demonstrated  no  
change  in  enzyme  activity  over  HkEC  alone  (data  not  shown)  and  were  not  analyzed  in  
any  experiments  described  in  this  dissertation.  
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Figure  13:  HO-­‐‑1  activity  was  induced  in  HkEC-­‐‑treated  Wt  liver  by  pretreatment  with  
hemin  or  2xCO.  Wt  mice  given  hemin  or  CO  prior  to  108  HkEC.  Mice  sacrificed  at  the  
time  of  HkEC  injection  (black  bars)  or  four  hours  later  (grey  bars).  HO-­‐‑1  activity  
approximated  using  CO  detection  by  gas  chromatography.  *p<0.05  vs  0h  HkEC,    #p<0.05  
vs  0h  matched  treatment.  (n=3-­‐‑4  per  group)  
  
After  establishing  that  hemin  and  CO  activated  HO-­‐‑1  enzyme  activity,  mRNA  
expression  was  then  evaluated  in  control  animals.  Wt  mice  were  given  hemin  or  2xCO  
alone  before  quantifying  hepatic  Nos2  and  Hmox1  mRNA  expression.  Hemin-­‐‑treated  
mice  were  evaluated  at  8  hours  and  2xCO-­‐‑treated  mice  at  four  hours  to  assess  mRNA  
levels  at  the  time  when  HkEC  would  be  administered  (0  hours,  relative  to  HkEC  
injection).  Hemin  treatment  induced  Nos2  and  Hmox1  expression  at  8  hours  with  Nos2  
expression  continuing  to  increase  through  24  hours  (Figure  14,  A-­‐‑B).  CO  treatment  had  
minimal  effects  on  mRNA  levels  for  either  gene  (Figure  14,  C-­‐‑D).  This  was  in  contrast  to  
previous  data  from  my  lab  and  from  other  labs  that  have  verified  the  ability  of  CO  to  
enhance  Hmox1  mRNA  expression.  This  discrepancy  is  unexplained,  but  could  
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potentially  indicate  baseline  Hmox1  gene  activation  in  some  healthy  control  animals  that  
disguised  fold  change  differences  at  low  levels  of  mRNA  induction.  
  
Figure  14:  Hepatic  Nos2  and  Hmox1  mRNA  expression  induced  in  hemin  but  
not  2xCO  control-­‐‑treated  mice.  Mice  were  given  A-­‐‑B:  hemin  or  C-­‐‑D:  2xCO  and  Nos2  
and  Hmox1  mRNA  quantified  using  qRT-­‐‑PCR.  Results  plotted  as  fold  change  vs  healthy  
control.  *p<0.05  vs  healthy  control.  (n=3  mice  per  group)  
  
Mice  were  then  pretreated  with  hemin  or  2xCO  prior  to  HkEC  challenge.  Four  
hours  later,  Nos2  expression  was  reduced  and  Hmox1  enhanced  by  hemin  and  2xCO  
relative  to  HkEC  alone;  this  was  not  statistically  significant  due  to  the  wide  range  of  
values  obtained  (Figure  15,  A-­‐‑B).  Fold  change  values  were  much  higher  than  those  seen  
in  Figure  12  because  samples  were  analyzed  on  the  StepOne  Plus  Real-­‐‑Time  PCR  
system,  which  exhibited  higher  sensitivity  than  the  7700  Sequence  Detector  System  used  
for  earlier  gene  quantification  (Figures  6-­‐‑7,  12,  14).  Protein  expression  correlated  with  
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mRNA  levels.  Six  hours  after  HkEC,  NOS2  protein  expression  was  inhibited  by  hemin  
and  2xCO  while  HO-­‐‑1  protein  levels  increased  with  both  treatments  (Figure  16).  
  
Figure  15:  HO-­‐‑1  activation  suppressed  hepatic  Nos2  and  increased  Hmox1  mRNA  
expression  during  HkEC  challenge.  Wt  mice  pretreated  with  hemin  or  2xCO  before  
HkEC.  Hepatic  A:  Nos2  and  B:  Hmox1  mRNA  expression  quantified  by  qRT-­‐‑PCR.  Results  
plotted  as  fold  change  vs  control.  *p<0.05  vs  healthy  controls.  (n=5  per  group)  
  
  
Figure  16:  HO-­‐‑1  activation  inhibited  NOS2  and  induced  HO-­‐‑1  protein  expression  in  
mouse  liver  relative  to  HkEC  alone.  Wt  mice  treated  with  hemin  or  2xCO  before  HkEC  
challenge.  Western  blot  of  HO-­‐‑1  and  NOS2  protein  expression  6  hours  after  HkEC.  




3.2. HO-­‐‑1  and  NF-­‐‑κB  activation  
Initiation  of  TLR4  signaling  by  Gram-­‐‑negative  PAMPs  leads  to  the  activation  of  
NF-­‐‑κB,  the  most  important  transcription  factor  involved  in  the  expression  of  NOS2  and  
pro-­‐‑inflammatory  cytokines.  To  determine  whether  hemin  and  CO  may  be  causing  
global  cytokine  suppression  in  HkEC-­‐‑challenged  liver,  the  gene  expression  profiles  of  
other  acute  phase  cytokines  were  examined.  Pro-­‐‑inflammatory  cytokines  TNF-­‐‑α,  IL-­‐‑6  
and  IFN-­‐‑γ  were  analyzed  because  they  represent  the  most  common  early  inflammatory  
mediators  produced  during  infection  and  all  were  attenuated  by  hemin  pretreatment  
(Figure  17,  A-­‐‑C).  Hemin  slightly,  but  not  significantly,  increased  the  expression  of  the  
anti-­‐‑inflammatory  cytokine,  IL-­‐‑10,  over  HkEC  alone  at  four  hours,  although  significant  
attenuation  was  observed  at  24  hours  (Figure  17D).      
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Figure  17:  Hemin  suppressed  hepatic  pro-­‐‑inflammatory  cytokine  expression  in  HkEC  
peritonitis.  Wt  mice  treated  with  HkEC  only  or  hemin+HkEC.  Liver  A:  TNF-­‐‑α,  B:  IL-­‐‑6,  C:  
IFN-­‐‑γ,  and  D:  IL-­‐‑10  mRNA  quantified  by  qRT-­‐‑PCR.  Results  plotted  as  fold  change  vs  
untreated  control.  *p<0.05  vs  control,  #p<0.05  vs  time-­‐‑matched  HkEC.  (n=5-­‐‑8  per  point)  
  
Pretreatment  with  2xCO  showed  a  more  complex  cytokine  profile.  CO  slightly  
augmented  IL-­‐‑6,  IFN-­‐‑γ,  and  IL-­‐‑10  expression  four  hours  after  HkEC  while  TNF-­‐‑α  was  
the  only  cytokine  to  be  mildly  suppressed  by  CO  (Figure  17,  A-­‐‑D).  One  explanation  for  
this  early  cytokine  enhancement  may  be  the  initial  cellular  stress  caused  by  CO  
exposure.  CO  is  known  to  bind  to  cytochrome  c  oxidase  and  increase  ROS  production  in  
mitochondria,  which  may  initially  exacerbate  early  inflammatory  responses.  However,  
ROS  ultimately  contribute  to  cytoprotection  through  mechanisms  such  as  increased  











































































genes  containing  anti-­‐‑oxidant  response  element  (ARE)  motifs  in  their  promoter  regions,  
and  activation  of  mitochondrial  biogenesis  [144-­‐‑146].  
  
Figure  18:  CO  suppressed  hepatic  cytokine  expression  when  given  prior  to  HkEC  
peritonitis.  Wt  mice  treated  with  HkEC  only  or  2xCO+HkEC.  Liver  A:  TNF-­‐‑α,  B:  IL-­‐‑6,  C:  
IFN-­‐‑γ,  and  D:  IL-­‐‑10  mRNA  quantified  by  qRT-­‐‑PCR.  Results  plotted  as  fold  change  vs  
untreated  control.  *p<0.05  vs  control,  #p<0.05  vs  time-­‐‑matched  HkEC.  (n=5-­‐‑8  per  point)  
  
Activation  of  NF-­‐‑κB  was  then  evaluated  by  comparing  expression  of  nuclear  p65  
to  total  p65.  Although  peak  NF-­‐‑κB  activation  is  detected  2–4  hours  after  challenge  [147],  
hepatic  nuclear  p65  remained  well  elevated  in  HkEC-­‐‑treated  mice  at  6  hours.  Hemin  and  
2xCO  both  reduced  p65  nuclear  accumulation,  as  seen  by  Western  blot  (Figure  19A)  and  





































































reduces  NF-­‐‑κB  in  murine  macrophages  [148]  and  HO-­‐‑1  silencing  promotes  NF-­‐‑κB  
activation  in  human  monocytes  [149].  
  
Figure  19:  Hemin  and  CO  suppression  of  HkEC-­‐‑induced  p65  nuclear  accumulation  in  
mouse  liver.  Wt  mice  treated  with  hemin  or  2xCO  before  HkEC  challenge.  A:  Western  
blot  of  6-­‐‑hour  nuclear  p65  with  histone  control  and  total  p65  with  GAPDH  control.  
Densitometry  used  to  plot  B:  total  plus  nuclear  p65  and  C:  nuclear:total  p65  ratio  as  fold  
change  vs  control.  Blot  is  representative  of  duplicate  experiments.  #p<0.05  vs  HkEC.  (n=2  
per  group)  
  
During  the  innate  response  to  inflammation,  nuclear  translocation  of  NF-­‐‑κB  
occurs  when  the  nuclear  scaffold  protein,  IκB  is  degraded,  releasing  NF-­‐‑κB  from  its  
cytoplasmic  sequestration.  To  evaluate  the  effect  of  HO-­‐‑1  activation  on  IκB,  total  
expression  of  the  subunit,  IκBα,  was  measured  by  Western  blot  analysis.  Total  IκBα  was  
slightly  increased  in  hemin-­‐‑pretreated  mice  (Figure  20,  A-­‐‑B),  suggesting  that  the  
activation  of  NF-­‐‑κB  may  be  facilitated,  in  part,  by  a  reduction  in  phosphorylation  and  


















































































results  in  the  nuclear  depletion  of  IκB  at  6  hours,  allowing  IκB  levels  to  recover  by  the  
time  of  my  observation.    To  test  these  theories,  quantification  of  nuclear  p65  and  total  
IκBα  at  an  earlier  time  point  (i.e.  two  hours)  would  have  provided  more  information  
regarding  temporal  activation  of  this  pathway.  Alternatively,  evaluating  IκB/NF-­‐‑κB  
status  in  hemin  or  2xCO  control  treated  mice  would  have  assessed  HO-­‐‑1-­‐‑dependent  NF-­‐‑
κB  activation,  although  this  was  not  performed  in  the  current  work.  
  
Figure  20:  Effects  of  hemin  and  CO  on  HkEC-­‐‑induced  IκBα   expression  in  
mouse  liver.  Wt  mice  treated  with  hemin  or  2xCO  before  HkEC  challenge.  A:  Western  
blot  of  6  hour  total  IκBα  with  GAPDH  control.  B:  Blots  densitized  and  plotted  as  fold  
change  vs  control.  Blot  is  representative  of  duplicate  experiments.  Results  do  not  achieve  
statistical  significance.  (n=2  per  group)  
  
The  data  shown  in  the  in  vivo  mouse  model  of  HkEC  peritonitis  demonstrates  
that  hemin  and  CO  can  reduce  the  expression  of  Nos2  mRNA  and  protein.  This  occurs  in  
GAPDH 






































conjunction  with  the  inhibition  of  NF-­‐‑κB  activation,  suggesting  that  HO-­‐‑1-­‐‑mediated  
immunosuppression  occurs,  at  least  in  part,  by  reducing  the  extent  of  downstream  TLR  
signal  transduction  in  response  to  LPS  challenge.
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4. The  role  of  HO-­‐‑1  in  NOS2  transcriptional  regulation  
during  in  vitro  LPS  challenge  of  hepatocytes  
After  demonstrating  that  HO-­‐‑1  activation  can  suppress  early  transcription  of  the  
hepatic  NOS2  gene  in  a  mouse  HkEC  peritonitis  model,  the  final  Aim  was  to  explore  the  
molecular  mechanism  for  this  relationship  using  an  in  vitro  approach  in  hepatic  cells.  To  
accomplish  this  objective,  murine  AML-­‐‑12  and  Hepa  1-­‐‑6  cell  lines  were  exposed  to  LPS  
with  or  without  TNF-­‐‑α.  Murine  liver  cell  lines  were  selected  for  these  experiments  to  
correlate  with  the  in  vivo  studies  in  mouse  liver.  HO-­‐‑1  activity  was  enhanced  using  
hemin,  a  proprietary  CO-­‐‑releasing  molecule  (CORM),  and  bilirubin;  inhibition  of  HO-­‐‑1  
was  accomplished  by  gene  silencing.  While  the  initial  intent  was  to  evaluate  the  effect  of  
HO-­‐‑1  on  the  recruitment  of  several  known  transcription  factors  to  the  Nos2  promoter,  
early  Nos2  transcriptional  control  in  vitro  was  not  affected  by  HO-­‐‑1  modifiers  as  seen  in  
vivo.  Subsequently,  the  work  presented  here  highlights  the  pattern  of  Nos2  gene  
expression  in  hepatocyte  cell  lines  and  some  limitations  of  the  chosen  in  vitro  model  for  
evaluating  HO-­‐‑1  effects  on  early  Nos2  induction.  A  visual  representation  of  the  
experimental  setup  is  shown  in  Figure  21.  Of  note,  CORMs  have  been  used  as  effective  
CO  delivery  systems  and  the  proprietary  CORM  used  in  this  experiment  is  notable  for  
its  increased  solubility,  stability  in  aqueous  media,  and  non-­‐‑toxic  metal  complex  that  
remains  after  CO  is  released  [150].  Additionally,  although  biliverdin  is  the  direct  
metabolite  of  HO-­‐‑1,  bilirubin  was  used  because  of  its  increased  stability  in  culture  
conditions.  
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Figure  21:  Experimental  design  for  in  vitro  studies.  AML-­‐‑12  or  Hepa  1-­‐‑6  cells  were  
exposed  to  hemin,  CORM,  or  bilirubin  1  hr  before  LPS  (10ug/mL)  with  or  without  TNF-­‐‑
α  (10ng/mL).  To  inhibit  NF-­‐‑κB,  Bay  11-­‐‑7082  was  given  30  minutes  prior  to  LPS  
challenge.  Cells  were  harvested  for  mRNA  at  indicated  times.    
  
4.1. AML-­‐‑12  cell  line  
To  evaluate  regulation  of  Nos2  gene  expression  by  HO-­‐‑1  in  cell  culture,  
experiments  were  first  performed  in  AML-­‐‑12  cells  grown  in  complete  DMEM/F-­‐‑12  
medium  to  70-­‐‑80%  confluence  before  being  treated  with  LPS+TNF-­‐‑α.  AML-­‐‑12  cells  are  
non-­‐‑transformed  mouse  hepatocytes  that  express  high  levels  of  human  transforming  
growth  factor  (TGF)-­‐‑α,  demonstrate  normal  hepatocyte  histology,  and  do  not  form  
tumors  in  vivo  [151].  Cells  were  exposed  to  a  range  of  LPS  +  TNF-­‐‑α  (hereafter  
abbreviated  as  LT)  concentrations  and  a  working  dose  of  10  µg/mL  LPS  +  10  ng/mL  
TNF-­‐‑α  was  selected  for  its  ability  to  adequately  induce  both  Nos2  and  Hmox1.  A  time  
course  study  demonstrated  that  Nos2  and  Hmox1  were  both  maximally  expressed  two  



















an  effort  to  best  simulate  mouse  in  vivo  experiments  where  maximal  Nos2  expression  
was  observed  four  hours  after  HkEC.    
  
Figure  22:  Nos2  and  Hmox1  mRNA  induction  peaks  2  hours  after  LT  challenge  
in  AML-­‐‑12  cells.  Cells  were  treated  with  LPS  (10  µg/mL)  +  TNF-­‐‑a  (10  ng/mL).  A:  Nos2  
and  B:  Hmox1  mRNA  quantified  by  qRT-­‐‑PCR.  Values  plotted  as  fold  change  vs  control.  
*p<0.05  vs  control.  (n=3-­‐‑4  per  time  point)  
  
Cells  were  pretreated  with  hemin,  CORM,  or  bilirubin  one  hour  before  LT  
exposure  and  Nos2  mRNA  levels  were  quantified  two  hours  later  using  qRT-­‐‑PCR.  In  
contrast  to  the  effects  of  HO-­‐‑1  activation  in  vivo,  induction  of  Nos2  mRNA  was  not  
attenuated  by  any  of  the  HO-­‐‑1  activators  (Figure  23).  Specifically,  hemin  and  CORM  had  
no  effect  while  40  µM  bilirubin  further  exacerbated  Nos2  expression.  Doses  of  
unconjugated  bilirubin  greater  than  25  µM  have  been  associated  with  apoptosis  in  
murine  hepatoma  Hepa  1c1c7  cells  [152],  which  may  have  accounted  for  the  Nos2  effects  



































     
Figure  23:  HO-­‐‑1  modifiers  do  not  suppress  Nos2  gene  expression  following  LT  
challenge  in  AML-­‐‑12  cells.  Cells  pretreated  with  hemin,  CORM,  bilirubin,  or  Bay  11-­‐‑
7082  prior  to  LT.  Nos2  mRNA  quantified  two  hours  later  using  qRT-­‐‑PCR.  Values  are  
plotted  as  fold  change  vs  untreated  control  and  representative  of  duplicate  experiments.  
*p<0.05  vs  control,  #p<0.05  vs  LT.  (n=3  per  group)  
  
To  verify  that  NF-­‐‑κB  mediated  the  induction  of  Nos2  expression  in  these  cells,  the  
NF-­‐‑κB  inhibitor,  Bay  11-­‐‑7082,  was  given  30  minutes  prior  to  endotoxin  challenge.  Bay11  
significantly  blunted  LT-­‐‑induced  Nos2  transcription,  but  the  values  were  still  greatly  
elevated  above  controls  (Figure  23).  AML-­‐‑12  cell  lines  are  transformed  by  human  TGF-­‐‑α  
and  a  previous  report  determined  that  these  cells  have  constitutively  active  NF-­‐‑κB  [153].  
Therefore,  it  is  possible  that  Nos2  transcriptional  induction  is  exaggerated  in  AML-­‐‑12  
cells,  counteracting  some  of  the  potential  effects  of  HO-­‐‑1  activation  by  hemin,  CORM,  or  
bilirubin.  Therefore,  murine  hepatoma  cell  lines  without  known  NF-­‐‑κB  aberrancy  were  















































4.2. Hepa  1-­‐‑6  cell  line  
4.2.1. Response  of  early  NOS2  transcription  to  HO-­‐‑1  activation  
Hepa  1-­‐‑6  cells  used  for  additional  in  vitro  studies  were  cultured  in  complete  
DMEM  medium  to  70-­‐‑80%  confluence  before  endotoxin  challenge.  The  LPS-­‐‑dependent  
transcriptional  response  in  Hepa  1-­‐‑6  cells  was  first  characterized  using  the  dose  of  LT  
administered  to  AML-­‐‑12  cells.  Under  these  conditions,  peak  Nos2  expression  was  
delayed  relative  to  that  seen  in  AML-­‐‑12  cells  with  peak  Nos2  mRNA  levels  observed  at  
six  hours  (Figure  24).  Alternatively,  Hepa  1-­‐‑6  cells  were  given  LPS  or  TNF-­‐‑α  alone  and  
analyzed  after  two  hours.  LPS  alone  activated  Nos2  and  Hmox1  transcription  more  than  
the  combined  LT  challenge,  suggesting  that  TNF-­‐‑α  attenuated  LPS-­‐‑mediated  expression.  
Time  course  analysis  of  LPS  alone  in  this  cell  line  revealed  maximal  induction  of  Nos2  
and  Hmox1  genes  at  two  hours  and  HO-­‐‑1  protein  at  six  hours  (Figure  25).  Therefore,  
subsequent  experiments  used  LPS  only,  rather  than  LT,  and  focused  on  gene  expression  




Figure  24:  Induction  of  Nos2  and  Hmox1  mRNA  by  LPS+TNFα   in  Hepa  1-­‐‑6  cells.  Cells  
were  treated  with  LPS  (10  µg/mL)  +  TNF-­‐‑a  (10  ng/mL),  LPS  alone  at  two  hours,  or  TNF  
alone  at  two  hours.  A:  Nos2  and  B:  Hmox1  mRNA  quantified  by  qRT-­‐‑PCR.  Values  
plotted  as  fold  change  vs  control.  LPS-­‐‑mediated  induction  was  suppressed  by  TNF-­‐‑α.    
*p<0.05  vs  control,  #p<0.05  vs  LPS.  (n=3-­‐‑4  per  time  point)  
  
  
Figure  25:  Induction  of  Nos2  and  Hmox1  by  LPS  alone  in  Hepa  1-­‐‑6  cells.  Cells  were  
treated  with  LPS  (10  µg/mL).  A:  Nos2  and  B:  Hmox1  mRNA  quantified  by  qRT-­‐‑PCR.  
Values  plotted  as  fold  change  vs  control.  *p<0.05  vs  control,  #p<0.05  vs  LPS.  (n=3-­‐‑4  per  
time  point)  C:  HO-­‐‑1  protein  expression  by  Western  with  tubulin  loading  control.  (n=3  
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Induction  of  HO-­‐‑1  was  achieved  by  pretreating  cells  with  the  enzyme  substrate,  
hemin,  and  downstream  mediators,  CORM  and  bilirubin,  one  hour  prior  to  LPS  
challenge.  All  HO-­‐‑1  activators  caused  a  2-­‐‑4-­‐‑fold  enhancement  of  two-­‐‑hour  Nos2  
expression  over  LPS  alone,  despite  these  doses  being  reported  in  other  cell  studies  
without  toxicity  (Figure  26).  Surprisingly,  CORM  caused  the  greatest  increase  in  Nos2  
transcription.  This  induction  by  CORM  may  reflect  early  oxidative  stress  that  precedes  
the  recruitment  of  protective  compensatory  pathways.    
     
Figure  26:  HO-­‐‑1  activation  exacerbates  acute  Nos2  transcription  in  LPS-­‐‑treated  Hepa  1-­‐‑
6  cells.  Cells  exposed  to  LPS  alone  or  with  1-­‐‑hour  pretreatment  of  hemin,  CORM,  or  
bilirubin  at  indicated  doses.  Values  plotted  as  fold  change  vs  control.  *p<0.05  vs  control,  
**p<0.05  vs  LPS,  #p<0.05  vs  control  and  LPS.  (n=3  per  group)  
  
Dose-­‐‑dependent  Nos2  expression  was  also  semi-­‐‑quantified  using  conventional  
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from  this  conventional  assay  showed  trends  that  differed  from  the  qRT-­‐‑PCR  data.  Lower  
doses  of  all  drugs  reduced  Nos2  mRNA  expression,  intermediate  doses  elicited  little  
change,  and  higher  doses  impaired  Nos2  transcription  except  for  CORM  (50  µM),  which  
further  induced  Nos2  mRNA  levels  (Figure  27).  One  potential  reason  for  the  
discrepancies  in  PCR  results  could  be  the  decreased  sensitivity  of  the  conventional  
assay.  Nos2  gene  expression  was  increased  by  ~300  hundred  fold  when  analyzed  by  
qRT-­‐‑PCR  while  conventional  RT-­‐‑PCR  showed  differences  of  only  25-­‐‑30  fold.  Therefore,  
conventional  amplification  of  Nos2  mRNA  in  Figure  27  may  inadequately  reflect  true  
quantities  of  this  highly  induced  message.    
  
Figure  27:  Conventional  RT-­‐‑PCR  quantification  of  Nos2  mRNA  in  LPS-­‐‑treated  Hepa  
1-­‐‑6  cells.  Cells  were  exposed  to  LPS  alone  or  with  one-­‐‑hour  pretreatment  of  hemin,  
CORM,  or  bilirubin  at  indicated  doses.  A:  Agarose  gel  visualization  of  PCR  product.  B:  
Densitometry  plotted  as  fold  change  vs  control  after  being  normalized  to  GAPDH  
































































Since  the  range  of  doses  for  hemin,  CORM,  and  bilirubin  pretreatment  in  the  
prior  experiment  had  similar  effects  on  Nos2  expression,  the  intermediate  doses  (12.5µM  
hemin,  25µM  CORM,  and  20µM  bilirubin)  were  selected  for  subsequent  studies.  Repeat  
analysis  of  Nos2  gene  expression  in  response  to  HO-­‐‑1  activators  showed  that  CORM  was  
the  only  compound  to  significantly  enhance  Nos2  transcription  (Figure  28A).  
Pretreatment  of  Hepa  1-­‐‑6  cells  with  Bay  11-­‐‑7082  confirmed  that  the  LPS-­‐‑mediated  Nos2  
transcriptional  response  was  entirely  NF-­‐‑κB  dependent.  However,  CORM  was  able  to  
induce  Nos2  transcription  in  the  presence  of  Bay-­‐‑11,  suggesting  that  it  does  so  by  a  NF-­‐‑
κB-­‐‑independent  mechanism  (Figure  28B).  Inactive  CORM  had  no  effect  on  LPS-­‐‑mediated  
Nos2  transcription.  Furthermore,  the  potent  antioxidant  drug,  N-­‐‑acetyl  L-­‐‑cysteine,  also  
blocked  the  effects  of  CORM  on  Nos2  induction  (Figure  29).  Collectively,  it  appears  that  
CO  initially  causes  mild  oxidative  stress  within  these  hepatocytes,  further  exacerbating  
early  Nos2  transcription  independent  of  NF-­‐‑κB.  An  alternative  explanation  may  be  the  
activation  of  protein  kinase  A  (PKA)/cAMP  by  CO,  thereby  recruiting  transcription  
factors  such  as  C/EBP  and  CREB  to  the  NOS2  promoter  [154].    
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Figure  28:  Effect  of  NF-­‐‑κB  inhibition  on  acute  Nos2  expression  in  LPS-­‐‑treated  Hepa  1-­‐‑
6  cells.  A:  Nos2  mRNA  in  cells  pretreated  with  hemin,  CORM,  bilirubin  or  Bay-­‐‑11.  B:  
Nos2  mRNA  response  to  HO-­‐‑1  activators  plus  Bay-­‐‑11.  Values  plotted  as  fold  change  vs  
control.  Enhanced  Nos2  transcription  by  CORM  is  NF-­‐‑κB-­‐‑independent.  *p<0.05  vs  
control,  #p<0.05  vs  LPS.  (n=3  per  group)  
  
     
Figure  29:  Characterization  of  enhanced  Nos2  expression  by  CORM  in  LPS-­‐‑treated  
Hepa  1-­‐‑6  cells.  Levels  of  Nos2  mRNA  in  cells  pretreated  with  CORM,  inactivated  
CORM,  or  N-­‐‑acetyl  L-­‐‑cysteine  (NAC)  prior  to  two-­‐‑hour  LPS  challenge.  Values  plotted  as  
fold  change  vs  control.  Enhanced  Nos2  transcription  by  CORM  occurs  via  oxidative  
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To  examine  the  impact  of  HO-­‐‑1  inhibition  on  Nos2  expression,  murine  Hmox1  or  
scrambled  (control)  shRNA  plasmids  were  transfected  into  Hepa  1-­‐‑6  cells.  After  resting  
for  24  hours,  transfected  cells  were  then  challenged  with  LPS  for  two  and  six  hours  to  
detect  mRNA  and  protein,  respectively.    Western  analysis  confirmed  that  HO-­‐‑1  was  
absent  in  Hmox1-­‐‑silenced  cells  and  induced  in  control-­‐‑transfected  cells  six  hours  after  
LPS  (Figure  30).    Additionally,  NOS2  protein  expression  was  slightly  higher  in  LPS-­‐‑
treated  Hmox1  silenced  cells  than  LPS-­‐‑treated  scrambled  shRNA  controls.  
Transcriptional  analysis  of  transfected  cells  two  hours  after  LPS  also  demonstrated  a  
modest  increase  in  Nos2  mRNA  levels  in  Hmox1  silenced  cells  (Figure  31).  In  the  absence  
of  HO-­‐‑1;  hemin,  CORM,  and  bilirubin  all  increased  Nos2  expression  over  LPS  alone.  The  
greatest  increase  in  Nos2  transcription  was  seen  in  the  presence  of  hemin,  perhaps  due  to  
the  toxicity  of  this  substrate  that  is  not  effectively  metabolized  in  cells  lacking  a  
functional  HO-­‐‑1  enzyme.  Overall,  these  findings  suggest  that  HO-­‐‑1  may,  in  fact,  exert  
some  inhibitory  control  on  Nos2  gene  expression.  However,  the  use  of  hemin,  CORM,  
and  bilirubin  in  the  current  in  vitro  model  is  not  enough  to  overcome  early  Nos2  
induction  by  LPS.  
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Figure  30:  Verification  of  Hmox1  silencing  in  Hepa  1-­‐‑6  cells.  Cells  were  transfected  
with  murine  Hmox1  or  scrambled  shRNA  and  evaluated  for  protein  expression  six  hours  
after  LPS.  A:  Western  blot  of  HO-­‐‑1  and  NOS2  protein  with  tubulin  loading  control.  
Densitometry  values  were  plotted  for  B:  HO-­‐‑1  and  C:  NOS2  proteins.  Data  is  
representative  of  duplicate  experiments.  *p<0.05  vs  scrambled  control,  #p<0.05  vs  
scrambled+LPS.  (n=2  per  group)  
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Figure  31:  Nos2  expression  in  HO-­‐‑1  silenced  Hepa  1-­‐‑6  cells.  Cells  were  
transfected  with  murine  Hmox1  or  scrambled  shRNA  and  evaluated  for  Nos2  expression  
after  two  hours  LPS.  Hemin,  CORM,  or  bilirubin  was  administered  one  hour  before  LPS  
as  indicated.  Values  are  plotted  as  fold  change  vs  control  and  representative  of  duplicate  
experiments.  p<0.05  for  all  groups  vs  control,  *p<0.05  vs  matched  shRNA+LPS,  #  p<0.05  
vs  matched  treatment.  (n=3  per  group)  
  
The  findings  described  in  Hepa  1-­‐‑6  cells  thus  far  show  that  HO-­‐‑1  activation  by  
one  hour  pretreatment  with  hemin,  exogenous  CO,  or  bilirubin  before  LPS  challenge  is  
unable  to  suppress  early  Nos2  mRNA  expression.  Instead,  CO  creates  oxidative  pressure  
on  hepatocytes,  which  exacerbates  two-­‐‑hour  LPS-­‐‑mediated  Nos2  expression.  Silencing  of  
HO-­‐‑1  does  lead  to  an  increase  in  Nos2  mRNA  expression,  suggesting  that  HO-­‐‑1  may  
exert  some  inhibition  on  Nos2.  However,  the  specific  model  used  in  this  aim  was  unable  
to  exaggerate  this  potential  relationship  during  the  acute  immune  phase  and  would  not  
be  useful  for  mechanistic  evaluation  of  HO-­‐‑1  repression  on  two-­‐‑hour  Nos2  transcription.  
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4.2.2. Response  of  late  phase  NOS2  transcription  to  HO-­‐‑1  activation  
To  determine  if  the  regulatory  potential  of  HO-­‐‑1  was  time-­‐‑dependent,  Nos2  
expression  24  hours  after  LPS  challenge  was  evaluated  under  the  conditions  described  
above.  As  expected,  LPS  generated  a  much  less  intense  Nos2  response,  increasing  only  
about  15  times  greater  than  control  (Figure  32).  Hemin  pretreatment  reduced  this  
expression  by  approximately  50%  while  the  modest  inhibition  by  bilirubin  did  not  reach  
statistical  significance.  Furthermore,  CORM  attenuated  Nos2  expression  by  
approximately  30%  but  without  reaching  significance  (Figure  33).  The  use  of  inactive  
CORM  or  CORM  with  NAC  both  reversed  this  suppression.    
  
Figure  32:  HO-­‐‑1  activation  attenuates  Nos2  transcription  24  hours  after  LPS  challenge  
in  Hepa  1-­‐‑6  cells.  Cells  were  pretreated  with  hemin  or  bilirubin  prior  LPS  exposure.  
Values  are  plotted  as  fold  change  vs  control  and  representative  of  duplicate  




























     
Figure  33:  Effect  of  CORM  pretreatment  on  24  hour  Nos2  expression  in  LPS-­‐‑treated  
Hepa  1-­‐‑4  cells.  Nos2  mRNA  quantified  in  cells  pretreated  with  CORM,  inactivated  
CORM,  or  N-­‐‑acetyl  L-­‐‑cysteine  (NAC)  prior  to  24  hour  LPS  challenge.  Values  plotted  as  
fold  change  vs  control.  Moderate  reduction  of  24  hour  Nos2  transcription  by  CORM  
depends  on  CO  release  and  is  reversed  by  NAC.  *p<0.05  vs  control.  (n=3  per  group)  
  
Once  differences  in  HO-­‐‑1  regulation  on  two  versus  24-­‐‑hour  Nos2  expression  
were  identified,  a  MTT  cell  growth  assay  was  used  to  determine  whether  this  was  
secondary  to  cell  cytotoxicity.  The  treatment  regimens  used  for  Hepa  1-­‐‑6  cells  were  not  
associated  with  any  significant  cell  death  at  two  or  24  hours  (Figure  34).  Increased  
conversion  of  tetrazolium  dye  was  observed  at  two  hours  with  the  treatment  of  
CORM+LPS  and  at  24  hours  with  LPS  only.  Since  the  MTT  assay  ultimately  reflects  
mitochondrial  metabolic  activity,  these  findings  corroborate  the  documented  ability  
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Figure  34:  MTT  assay  evaluating  metabolic  activity  and  toxicity  in  Hepa  1-­‐‑6  cells  2  
and  24  hours  after  LPS.  Cells  cultured  in  96-­‐‑well  plates  were  pretreated  with  hemin,  
CORM,  and  bilirubin  with  or  without  LPS.  MTT  reagent  was  added  at  two  or  24  hours  
and  color  development  terminated  four  hours  later.  Absorbance  values  were  obtained  at  
570  nm  and  plotted  as  percentage  of  untreated  cells.  Graph  is  representative  of  duplicate  
experiments.  *p<0.05  vs  control,  #p<0.05  vs  LPS  only.  
  
From  the  work  presented  in  this  Aim,  it  is  evident  that  HO-­‐‑1  regulation  of  Nos2  
transcription  is  more  complex  than  originally  hypothesized,  showing  variability  in  acute  
versus  late  stage  in  vivo  inflammation.  HO-­‐‑1  activators  were  unable  to  inhibit  early,  two-­‐‑
hour  induction  of  Nos2  although  transcription  was  enhanced  in  cells  deficient  in  HO-­‐‑1.  
In  contrast,  Nos2  expression  was  reduced  with  hemin,  CORM,  and  bilirubin  
pretreatment  when  evaluated  24  hours  after  LPS  exposure.  These  temporal  differences  















































expression.  Alternatively,  a  specific  degree  of  HO-­‐‑1  activation  could  be  required  for  this  
pathway  to  have  any  transcriptional  influence;  perhaps  this  threshold  was  reached  24  
hours  after  endotoxin  challenge  but  not  at  two  hours.  Suggestions  for  modifications  of  
the  model  and  potential  experiments  that  would  further  explore  these  theories  will  be  
described  in  the  next  chapter.  
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5. Conclusions  
5.1. Interpretation  of  the  main  findings  and  their  limitations  
The  work  presented  in  this  dissertation  brings  attention  to  two  poorly  defined  
areas  within  the  literature:  1)  the  supportive  role  of  NOS2  in  mitochondrial  biogenesis  
and  2)  the  mechanism  by  which  the  heme  oxygenase-­‐‑1/CO  system,  another  key  
regulator  of  mitochondrial  biogenesis,  may  counter  Nos2  transcription  activation  in  the  
liver.  The  work  presented  here  demonstrated  that  NOS2  participates  not  only  in  cellular  
damage  during  sepsis,  but  is  also  necessary  for  prompt  recovery  following  that  injury.  
NOS2  is  required  for  optimal  activation  of  the  mitochondrial  biogenesis  pathway.  In  the  
absence  of  Nos2,  damage  to  mtDNA  cannot  be  repaired  because  the  expression  of  both  
nuclear  and  mitochondrial  proteins  needed  for  this  process  is  diminished.  Additionally,  
impaired  nuclear  and  mitochondrial  protein  accumulation  in  NOS2-­‐‑deficient  mice  is  
associated  with  decreased  activation  of  the  pro-­‐‑survival  kinases,  Akt  and  AMP  kinase.  
The  association  of  NOS2  with  these  kinases  connects  NOS2  to  mitochondrial  biogenesis  
but  also  offers  a  potential  avenue  by  which  NOS2  may  interact  with  a  number  of  other  
pro-­‐‑survival  pathways  such  as  glucose  metabolism,  angiogenesis,  and  cell  cycle  
progression  [155-­‐‑158].  Nevertheless,  my  lab  has  also  demonstrated  that  NOS2  is  
necessary  for  activation  of  mitochondrial  biogenesis  in  the  liver,  in  part  by  facilitating  
protein  importation  across  the  mitochondrial  membranes.  S-­‐‑nitrosylation  of  Hsp60  was  
shown  to  be  necessary  for  the  importation  of  Tfam  into  the  mitochondria  following  
HkEC  peritonitis  [135].  Fundamentally  then,  NOS2  is  indispensible  for  mitochondrial  
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repair  after  acute  inflammation,  so  ways  to  regulate  NO  production  and  optimize  NOS2-­‐‑
specific  cytoprotective  pathways  should  continue  to  be  explored  in  the  future.  
The  second  Aim  of  this  dissertation  was  to  explore  the  potential  regulatory  
relationship  between  the  HO-­‐‑1/CO  system  and  NOS2.  This  approach  to  Nos2  
transcriptional  control  is  favorable  because  HO-­‐‑1  provides  a  link  that  could  combine  
immunomodulation  with  mitochondrial  biogenesis,  simultaneously  subverting  cellular  
damage  and  allowing  compromised  mitochondria  to  be  repaired  or  replaced.  In  a  
murine  model  of  HkEC-­‐‑peritonitis,  current  data  shows  that  HO-­‐‑1/CO  disrupts  acute,  
high–level  Nos2  expression,  in  part  by  antagonizing  NF-­‐‑κB  activity.  It  is  a  valid  
argument  that  the  HkEC  mouse  model  used  here  is  not  the  ideal  surrogate  for  clinical  
sepsis  for  reasons  stated  previously.  However,  one  must  consider  that  if  HO-­‐‑1  can  
attenuate  an  intense  NOS2  induction  like  that  elicited  by  HkEC,  it  would  likely  be  
effective  in  actual  live  sepsis,  which  is  characterized  by  a  more  gradual  increase  in  
cytokine  and  NOS2  expression.    Moreover,  it  has  been  shown  in  our  laboratory  that  a  
close  relationship  exists  between  HO-­‐‑1  and  counter-­‐‑inflammation  in  murine  E.  coli  fibrin  
clot  sepsis,  a  more  accepted  correlate  for  the  human  response  to  sepsis  [120].  Therefore,  
confirmation  of  the  HO-­‐‑1/CO-­‐‑mediated  regulatory  control  on  mitochondrial  biogenesis  
and  immunomodulation  in  a  fibrin  clot  model  of  murine  sepsis  provides  plausibility  for  
application  of  this  system  to  human  disease.  
When  attempting  to  recapitulate  the  mouse  in  vivo  findings  in  a  hepatocyte  cell  
culture  system,  critical  design  flaws  limited  the  conclusions  that  could  be  made  about  
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the  possible  counter-­‐‑regulation  of  the  two  systems  of  interest.  In  stark  contrast  to  several  
studies  reporting  HO-­‐‑1  attenuation  of  NOS2,  the  strategy  used  here  to  enhance  HO-­‐‑1  
activity  in  LPS-­‐‑treated  AML-­‐‑12  and  Hepa  1-­‐‑6  hepatocytes  was  unable  to  suppress  early  
peak  Nos2  mRNA  expression.  Conversely,  24-­‐‑hour  Nos2  transcription  was  more  
responsive  to  HO-­‐‑1  control.  The  majority  of  in  vitro  studies  addressing  this  HO-­‐‑1/NOS2  
counter-­‐‑regulation  have  analyzed  NOS2  expression  at  later  time  points,  i.e.  18  or  24  
hours.  Three  theories  may  explain  why  these  temporal  differences  may  exist.  First,  HO-­‐‑1  
may  not  have  been  induced  early  enough  to  influence  transcriptional  networks  directed  
at  the  Nos2  promoter  immediately  following  LPS  exposure.  In  response  to  LPS  alone,  
HO-­‐‑1  protein  expression  is  highest  at  six  hours  (Figure  25),  whereas  peak  Nos2  mRNA  
expression  occurs  at  two  hours  (Figure  22).  NF-­‐‑κB  nuclear  translocation  occurs  30-­‐‑60  
minutes  after  LPS  exposure  in  cell  culture  [159],  simultaneously  targeting  both  Nos2  and  
Hmox1  promoters.  Therefore,  pretreatment  with  hemin,  CORM,  and  bilirubin  just  one  
hour  prior  to  LPS  administration  may  not  enhance  HO-­‐‑1  early  enough  to  block  NF-­‐‑κB  or  
other  transcription  factors  that  facilitate  initial  acute  Nos2  promoter  activation.  Second,  it  
is  also  probable  that  Nos2-­‐‑specific  transcriptional  complexes  employed  at  24  hours  differ  
significantly  from  that  at  two  hours.  It  is  well  understood  that  several  transcription  
factors  are  required  for  optimal  expression  of  Nos2  but  whether  certain  combinations  
have  activating  versus  inhibitory  roles  is  unclear.  Finally,  the  dose  of  LPS  used  for  this  
study  may  overwhelm  any  HO-­‐‑1  dependent  repression  that  may  have  occurred  early  in  
the  time  course.  It  is  unclear  how  the  dose  used  in  cell  culture  systems  correlates  to  
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clinical  endotoxin  exposure,  but  with  such  high  Nos2  induction  seen  in  this  model,  it  is  
possible  that  more  significant  HO-­‐‑1  regulation  would  be  evident  at  lower  LPS  doses.  
Suggestions  for  in  vitro  model  adjustments  and  ideas  for  potential  experiments  to  
explore  some  of  these  theories  are  presented  in  the  Future  Directions  section  below.  
The  work  presented  here  does  provide  additional  information  about  the  role  and  
regulation  of  NOS2  during  Gram-­‐‑negative  challenge.  It  demonstrated  that  NOS2  
protects  against  mitochondrial  and  cellular  dysfunction  through  mitochondrial  
biogenesis.  Furthermore,  it  suggests  that  a  pathway  known  to  promote  mitochondrial  
biogenesis  can  also  offer  negative  feedback  regulation  on  Nos2  transcription.  HO-­‐‑1  
appears  to  exert  negative  regulatory  control  on  Nos2  in  mouse  liver,  but  additional  
confirmatory  studies  should  be  paired  with  more  advanced  studies  of  the  molecular  
mechanism  in  cell  culture  models.  
5.2. Future  Direction  
After  summarizing  the  conclusions  from  this  dissertation  project,  several  
questions  regarding  the  liver-­‐‑specific  HO-­‐‑1/NOS2  relationship  were  not  answered  due  
to  limitations  of  the  in  vitro  and  in  vivo  models.  In  the  mouse  model,  HO-­‐‑1  activators  
were  administered  prior  to  HkEC  but  no  model  suppressing  HO-­‐‑1  activity  was  
generated  for  comparison.  This  could  be  accomplished  in  several  ways.  Classically,  
chemical  inhibition  of  HO-­‐‑1  was  accomplished  through  the  use  of  metalloporphyrins,  
such  as  zinc  protoporphyrin  IX  (ZnPP)  and  tin  protoporphyrin  IX  (SnPP).  These  
compounds  are  potent  inhibitors  of  heme  oxygenase  but  also  interfere  with  NOS  activity  
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[160,  161],  making  them  a  poor  choice  for  use  in  studies  evaluating  both  HO  and  NOS  
enzymes.  Another  option  is  the  use  of  genetically  engineered  mice.  Mice  with  
homozygous  deletion  of  Hmox1  have  low  postnatal  survival  and  display  anemia,  iron  
accumulation  in  kidney  and  liver,  and  chronic  inflammation  [162].  However,  Hmox1  
conditional  knockout  mice  have  been  described  for  studies  in  myeloid  cells  [163]  and  
could  be  explored  for  liver  specific  deletion  of  HO-­‐‑1.  Mice  with  liver-­‐‑specific  ablation  of  
Hmox1  could  then  be  challenged  with  live  or  HkEC  to  determine  effects  on  Nos2  
transcription.  HO-­‐‑1  can  also  be  transiently  silenced  in  Wt  mice  using  in  vivo  siRNA.  Use  
of  RNA  interference  has  been  limited  to  cell  culture  because  of  rapid  degradation,  
impeded  cellular  uptake,  and  heightened  immune  responses  when  long  RNA  segments  
have  been  administered  in  vivo  [164].    However,  Merck  &  Co.,  Inc.  have  successfully  
improved  this  technique  by  creating  a  lipid  nanoparticle  (LNP)  delivery  system  that  
effectively  delivers  siRNA  via  tail  vein  injection  with  minimal  immune  reactivity  [165,  
166].  If  performing  this  experiment,  Hmox1  siRNA  would  be  designed  and  assembled  
into  LNPs  administered  to  C57BL/6  mice  by  tail  vein  injection.  These  mice  could  then  be  
used  to  evaluate  the  impact  of  HO-­‐‑1  deficiency  on  Nos2  expression  and  upstream  
regulatory  pathways.    
The  in  vitro  data  presented  in  Chapter  4  could  also  be  enhanced  by  a  few  
additional  experiments.  The  temporal  expression  of  HO-­‐‑1  protein  was  not  evaluated  
following  hemin,  CORM,  and  bilirubin  but  this  might  address  whether  these  reagents  
stimulate  HO-­‐‑1  function  earlier  than  LPS  alone  –  before  Nos2  transcription  is  initiated.  
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Therefore,  the  pretreatments  could  be  given  more  than  an  hour  before  LPS  to  ensure  that  
HO-­‐‑1  is  activated  before  Nos2  is  expressed.  Alternatively,  the  gold  standard  for  
evaluating  potential  therapeutic  HO-­‐‑1  activation  would  be  to  use  an  overexpression  
vector  to  ensure  HO-­‐‑1  protein  is  expressed  prior  to  endotoxin  challenge.  In  addition  to  
the  shRNA  constructs  used  in  this  project,  Origene  provides  an  Hmox1  cDNA  ORF  clone  
in  a  pCMV6-­‐‑AC-­‐‑GFP  cloning  vector  that  could  be  transfected  into  Hepa  1-­‐‑6  cells.  In  
contrast,  additional  evaluation  of  the  effect  of  HO-­‐‑1  inhibition  would  be  useful.  Hmox1  
silenced  cells  were  used  to  evaluate  Nos2  expression  two  hours  post  LPS  challenge  but  
the  degree  of  transcriptional  response  was  not  quantified  at  24  hours.  Comparison  of  
Nos2  expression  at  two  and  24  hours  in  this  system  may  have  revealed  whether  inherent  
transcriptional  control  was  significantly  different  during  early  vs  late  inflammation.  
One  of  the  significant  limitations  of  prior  studies  relating  the  HO-­‐‑1/CO  and  
NOS2  pathways  is  the  characterization  of  specific  changes  in  transcriptional  complexes  
at  the  Nos2  promoter.  Reports  have  suggested  that  NF-­‐‑κB  and  STAT-­‐‑1  are  affected  by  
HO-­‐‑1  activity  but  studies  have  inadequately  established  that  this  directly  impacts  Nos2  
transcription  during  inflammation.  Future  evaluation  should  therefore  evaluate  changes  
in  direct  transcription  factor  binding,  i.e.  by  NF-­‐‑κB,  Stat-­‐‑1,  CREB  and  IRF-­‐‑1  by  chromatin  
immunoprecipitation  (ChIP).  Luciferase  reporter  systems  are  also  useful  for  defining  
promoter  regions  and  could  be  used  in  this  case.  Perrella,  et  al.  has  designed  murine  Wt  
and  mutated  NOS2  luciferase  reporters  that  would  be  ideal  for  application  in  this  cell  
culture  model  [167,  168].    These  constructs  were  used  in  macrophages  challenged  with  
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LPS  to  show  that  the  distamycin  A,  an  antibody  that  binds  the  DNA  minor  groove  and  
interferes  with  IRF-­‐‑1  binding,  reduces  Nos2  expression  and  protects  from  LPS  
endotoxemia  [169].  This  suggests  that  additional  evaluation  of  individual  and  
collaborative  binding  of  transcription  factors  on  the  Nos2  promoter  would  provide  more  
definitive  information  on  a  major  regulatory  target  for  treatment  of  inflammatory  
diseases  such  as  sepsis.    
Ultimately,  the  information  gained  from  studies  in  mouse  models  would  need  to  
be  translated  to  a  human  system  for  clinical  relevance.  While  human  HepG2  or  primary  
hepatocytes  could  be  utilized  for  in  vitro  studies,  caution  must  be  taken  since  the  human  
and  mouse  Nos2  promoters  vary  greatly  and  share  little  homology.  For  instance,  two  
additional  AP-­‐‑1  sites  and  one  NF-­‐‑κB  site  are  important  for  human  Nos2  promoter  
activity  but  are  not  present  in  the  mouse  promoter  [170].  Therefore,  evaluation  of  the  
specific  transcriptional  complexes  involved  in  Nos2  expression  will  need  to  
accommodate  these  differences.    
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Appendix:  Materials  and  Methods  
Reagents  
LPS  (from  E.  coli  0111:B4,  Sigma,  St.  Louis,  MO)  was  dissolved  in  sterile  water  
and  used  at  a  final  concentration  of  10µg/mL.  TNF-­‐‑α  was  obtained  from  Prospec  Bio  
(Israel),  reconstituted  in  water,  and  used  at  10  ng/mL.  Hemin  in  0.1%  DMSO  (Sigma),  
was  used  at  50  µmol/kg  in  animal  studies  and  5,  12.5,  or  25  µM  in  cell  culture.  The  
proprietary  CORM-­‐‑2  compound  (CORM)  was  a  gift  from  Fabio  Zobi  at  the  University  of  
Zurich  and  was  used  at  a  final  concentration  of  25  µM  in  0.1%  DMSO  [150].  The  half-­‐‑life  
of  CO  release  from  CORM  is  20  minutes,  so  fresh  CORM  solution  was  prepared  
immediately  prior  to  each  experiment.  To  inactivate  CORM,  CO  was  released  by  
incubation  of  the  compound  in  media  for  30  minutes  before  applying  to  cells.  Bilirubin  
(USB  Corp)  was  dissolved  in  0.1N  NaOH  to  a  working  concentration  of  15  mM  and  
administered  to  cells  at  a  final  concentration  of  10,  20,  or  40µM.  N-­‐‑acetyl  L-­‐‑cysteine  
(Sigma)  was  dissolved  in  water  for  final  concentration  of  10  mM.  Bay  11-­‐‑7082  was  
resuspended  in  water  and  used  at  a  final  concentration  of  50  µM.  Lipofectamine  2000  
(Invitrogen)  was  used  for  shRNA  transfections.  
Antibodies  used  for  Western  blots  included  NRF-­‐‑1,  PGC-­‐‑1α,  Tfam,  Pol-­‐‑γ,  histone  
H3,  NF-­‐‑κB  p65,  IκBα  (Santa  Cruz),  NOS2  (Millipore),  TLR4  and  HO-­‐‑1  (StressGen),  
GAPDH  (GeneTex),  and  tubulin  (Sigma).  Taqman  real-­‐‑time  RT-­‐‑PCR  (qRT-­‐‑PCR)  primers  
were  all  obtained  from  Applied  Biosystems  and  included  mouse  Nos2,  Hmox1,  
cytochrome  b,  TNF-­‐‑α,  IL-­‐‑6,  ICAM-­‐‑1,  IL-­‐‑1β,  IFN-­‐‑γ,  and  IL-­‐‑10.  
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Mouse  Studies.  
C57BL/6J  and  NOS2-­‐‑/-­‐‑  mice  used  in  animal  experiments  were  obtained  from  
Jackson  Laboratories  (Bar  Harbor,  ME)  and  the  NOS2  mice  bred  at  our  institution.  TLR4-­‐‑
/-­‐‑  mice  were  generously  provided  by  Dr.  S.  Akira  of  Osaka  University  [10,  34]  and  then  
speed  congenically  backcrossed  onto  a  C57BL/6J  background.  For  immunofluorescence  
studies,  transgenic  reporter  mice  expressing  green  fluorescent  protein  (GFP)  exclusively  
in  mitochondria  (mtGFP-­‐‑tg)  were  a  gift  from  Hiroshi  Shitara  and  Hiromichi  Yonekawa  
of  Tokyo  Metropolitan  Institute  of  Medical  Science  [171].  Mice  were  kept  in  pathogen-­‐‑
free  housing  on  dry  bedding  and  studies  were  conducted  with  20–25  g  males  on  
approved  protocols  that  conform  to  the  NIH  Guide  for  the  Care  and  Use  of  Laboratory  
Animals.  
Surgical  implantation  of  a  fibrin  clot  containing  108  CFU  E.  coli  was  performed  on  
mice  anesthetized  with  intraperitoneal  ketamine  and  xylazine.  The  abdomen  was  
shaved  and  cleaned  with  povidone-­‐‑iodine.  A  midline  laparotomy  was  performed  and  
the  infected  clot  inserted  into  the  peritoneum.  The  peritoneum  and  abdomen  were  
closed  with  proline  sutures  and  mice  were  resuscitated  with  1  mL  of  subcutaneous  0.9%  
NaCl.  Mice  included  in  the  survival  study  were  monitored  for  seven  days  with  free  
access  to  food  and  water.  Mice  used  for  quantification  of  bacterial  burden  were  
sacrificed  24  hours  following  surgery  by  overexposure  to  isoflurane  and  blood  was  
collected  from  the  heart  using  syringe  aspiration.    
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Mice  treated  with  1  x  108  HkEC  were  injected  intraperitoneally  with  0.5  mL  
bacteria  in  sterile  saline.  Animals  were  harvested  at  4,  6,  or  24  hours  following  this  
injection  by  overexposure  to  isoflurane  and  liver  or  heart  were  snap-­‐‑frozen  and  stored  at  
-­‐‑80°C.  Healthy  controls  were  also  sacrificed  in  this  same  manner.  Pretreatment  studies  
involved  subcutaneous  injection  of  hemin  8  hours  before  HkEC  exposure.  CO  was  
inhaled  for  one  hour  at  250  ppm  four  hours  before  and  again  immediately  following  
HkEC  injection.  This  dose  of  CO  has  been  associated  with  10%  carboxyhemoglobin  
levels,  <1%  methemoglobin,  and  induction  of  mitochondrial  biogenesis  [172].  
Mice  injected  with  HkEC  were  killed  under  anesthesia  at  0,  4,  6,  24,  and  72  h  and  
the  hearts  or  livers  collected  immediately.  The  organs  were  flash-­‐‑frozen  in  liquid  
nitrogen  for  all  mRNA  and  protein  analysis  and  stored  at  −80  °C  until  processed.  Hearts  
for  immunofluorescence  studies  were  fresh-­‐‑fixed  in  10%  formalin  for  24  h  and  then  
stored  in  70%  ethanol  and  phosphate-­‐‑buffered  saline  until  processed  as  described  below.  
Bacterial  Preparation  
Live  bacteria  were  grown  from  lyophilized  E.  coli  stored  at  -­‐‑80°C  (serotype  
086a:K61;  American  Type  Tissue  Culture  Collection,  Rockville,  MD,  USA)  by  inoculating  
them  on  sterile  agar  slants  and  incubating  at  37°for  18  hours.  Bacteria  were  resuspended  
to  a  concentration  of  109  CFU/mL  the  morning  of  the  surgery  using  previously  described  
methods  [173].  Fibrin  clots  were  prepared  by  suspending  108  CFU  E.  coli  in  500  µL  fibrin  
(500  µL  of  10  mg/mL  bovine  fibrinogen  plus  10  µL  of  1.2  U/µL  bovine  plasma  thrombin,  
Sigma).      
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To  prepare  heat-­‐‑killed  E.  coli  (HkEC),  a  solution  with  an  approximate  
concentration  of  1  x  1010  CFU/mL  was  heat-­‐‑inactivated  at  65°C  for  1  hour  and  stored  at  -­‐‑
80°C  until  use.    Final  quantification  of  the  bacterial  solution  was  achieved  by  counting  
pour  plate  colonies  of  a  sample  removed  prior  to  heating.    Efficacy  of  heat-­‐‑inactivation  
was  >  99.9%  as  verified  by  pour  plates.  HkEC  were  thawed  once  and  diluted  with  sterile  
0.9%  NaCl  to  a  concentration  of  2×108  CFU/mL  and  0.5  ml  was  administered  by  single  
intraperitoneal  injection  to  groups  of  three  to  six  mice  per  time  point.  Preliminary  
studies  showed  that  this  sublethal  dose  of  bacteria  was  subnecrotic  in  heart  and  liver  
and  lacked  mortality  in  the  mice  used  for  this  study.    
To  determine  bacterial  burden,  blood  from  cardiac  aspiration  was  mixed  with  
heparin  to  prevent  clotting,  serially  diluted  using  sterile  water,  and  plated  on  LB  agar  
plates.  Inoculated  plates  were  incubated  at  37°C  for  18  hours  and  observed  for  colony  
growth.  
Cell  Culture  
Mouse  AML-­‐‑12  cells  were  obtained  from  ATCC  (Manassas,  VA)  and  cultured  in  
5%  CO  in  DMEM/F-­‐‑12  medium  (GIBCO)  supplemented  with  10%  FBS,  5  µg/mL  insulin,  
5  µg/mL  transferrin,  5  ng/mL  selenium,  40  ng/mL  dexamethasone,  and  1x  antimycotic  
antibiotic  (GIBCO).  Cells  were  treated  with  LPS  (10  µg/mL)  +  TNF-­‐‑α  (10  ng/mL)  upon  
reaching  70-­‐‑80%  confluence.  Hepa  1-­‐‑6  cells  were  obtained  from  ATCC  (Manassas,  VA)  
and  cultured  in  5%  CO  in  DMEM  medium  (GIBCO)  supplemented  with  10%  FBS  and  1x  
antimycotic  antibiotic.  Transfection  studies  were  conducted  at  50%  confluence  while  
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other  studies  were  initiated  at  70-­‐‑80%  confluence.  Following  treatment,  cells  were  frozen  
at  -­‐‑80°C  until  processed  for  mRNA  or  protein.  
Hemin,  CORM,  and  bilirubin  were  administered  one  hour  before  adding  LPS  to  
the  media.  Bay  11-­‐‑7082  was  given  30  minutes  before  LPS.  
Cell  Transfection  
Hmox1  and  scrambled  shRNA  plasmids  were  obtained  from  Origene  (Rockville,  
MD)  and  amplified  by  first  transforming  the  plasmids  into  NEB  5α  supercompetent  E.  
coli  cells  according  to  the  manufacturer’s  protocol  (Biolabs,  Ipswich,  MA).  In  brief,  
transformed  bacteria  were  plated  on  LB  agar  with  25  µg/mL  kanamycin  overnight  after  
which  a  single  colony  was  selected  for  expansion.  Bacteria  were  grown  overnight  in  LB  
medium  with  25  µμg/mL  kanamycin  and  pelleted  by  centrifugation  at  6,000g  for  15  
minutes.  Plasmids  were  purified  using  the  Endofree  Plasmid  Maxi  Kit  according  to  the  
manufacturer’s  protocol  (Qiagen).  In  brief,  bacteria  were  lysed  and  passed  through  a  
syringe  filter  to  remove  cellular  debris.  Filtered  lysate  was  applied  to  a  DNA  binding  
column,  washed,  and  eluted  with  isopropanol.  DNA  was  centrifuged  and  the  pellet  
washed  in  70%  ethanol  before  being  resuspended  in  endotoxin-­‐‑free  buffer.  Plasmid  
concentration  was  determined  by  spectrophotometry  at  260  nm  and  quality  was  checked  
using  agarose  gel  electrophoresis.  Plasmids  were  diluted  to  a  concentration  of  1  µg/µL  
for  transfections.    
Hepa  1-­‐‑6  cells  were  cultured  to  50%  confluence  and  then  transfected  using  
Lipofectamine  2000  in  2:1  ratio  with  Hmox1  or  scrambled  shRNA  plasmids,  achieving  
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efficiency  of  >90%.  After  24  hours,  transfection  media  was  removed  and  cells  were  
allowed  to  rest  in  fresh  complete  medium  for  24  hours.  Cells  were  then  pretreated  with  
hemin,  CORM,  or  bilirubin  one  hour  before  LPS  was  added  and  cells  harvested  at  two  
hours  for  mRNA  analysis  and  six  hours  for  protein  verification.  
Nuclear  and  total  protein  isolation  
While  isolating  nuclei  from  frozen  liver,  samples  were  kept  on  ice  at  all  times.  
Approximately  0.5  g  frozen  liver  tissue  was  first  homogenized  in  Buffer  A  (250  mM  
sucrose,  5  mM  MgCl2,  10  mM  Tris/HCl,  pH  7.4)  with  1x  protease  and  phosphatase  
inhibitors.  Homogenate  was  centrifuged  at  600g  for  15  minutes,  pellet  washed  once  in  
Buffer  A,  and  resuspended  in  Buffer  B  (2  M  sucrose,  1  mM  MgCL2,  and  10  mM  Tris/HCl,  
pH  7.4)  with  inhibitors.  Nuclei  were  centrifuged  at  16,000g  for  30  minutes  and  
supernatant  and  fatty  debris  removed  to  leave  just  a  clean  nuclear  pellet.  Nuclei  were  
resuspended  in  RIPA  buffer  with  inhibitors,  sonicated,  and  centrifuged  at  max  speed  for  
15  minutes  to  obtain  nuclear  protein.  Protein  concentration  was  quantified  using  the  
Bicinchoninic  acid  (BCA)  protein  assay.  
To  prepare  tissue  for  Western  blotting,  hearts  were  divided  longitudinally  so  that  
atrial  and  ventricular  tissues  were  represented  in  each  sample.  Approximately  0.2  g  
frozen  liver  tissue  was  used  to  prepare  liver  homogenate.  Total  protein  was  obtained  by  
mechanically  homogenizing  liver  or  cardiac  tissue  in  complete  RIPA  buffer  with  
protease  and  phosphatase  inhibitors.  Homogenate  was  solicited  and  centrifuged  at  max  
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speed  for  15  minutes  at  4°C.  Supernatant  was  decanted  and  quantified  using  the  BCA  
protein  assay.  
HO-­‐‑1  activity    
HO  enzyme  activity  was  measured  in  liver  homogenates  using  the  reduction  gas  
method  for  the  analysis  of  CO  byproduct  [174].  Frozen  mouse  liver  tissue  was  weighed,  
mechanically  homogenized,  and  briefly  sonicated  in  4  volumes  of  0.1  M  potassium  
phosphate,  pH  7.4.  After  centrifuging  at  13,000g  for  2  minutes  at  4°C,  supernatant  was  
collected  for  enzyme  activity  and  protein  assay.  Sample  homogenate  was  mixed  with  
hemin/albumin  substrate  and  NADPH  before  placing  vials  in  37°C  water  bath  for  30  
minutes.    The  reaction  was  stopped  with  60%  5’-­‐‑sulfosalicylic  acid  (SSA).  CO  generation  
was  detected  using  RGA5  Process  Gas  Analyzer  (Trace  Analytical,  Menlo  Park,  CA)  and  
normalized  to  sample  protein  concentration  to  obtain  values  of  nmol  CO/g/30  min.  
Western  blot  analysis  
Total  and  nuclear  protein  samples  were  prepared  in  2x  Laemmli  buffer  +  DTT.  
After  heating  at  95°C  for  10  minutes,  protein  samples  were  separated  by  SDS-­‐‑PAGE  and  
transferred  to  PVDF  membranes  for  Western  analysis.  Membranes  were  blocked  in  5%  
milk  in  TBST  and  then  incubated  with  validated  polyclonal  or  monoclonal  antibodies  
against  PGC-­‐‑1α,  NRF1,  Tfam,  Pol-­‐‑γ,  Akt,  pAkt,  AMPK,  p-­‐‑AMPK,  NOS2,  HO-­‐‑1,  p65,  or  
IκBα.  Anti-­‐‑tubulin,  GAPDH,  histone  or  porin  was  used  as  a  loading  control.  After  three  
washes  in  TBST,  membranes  were  incubated  in  HRP-­‐‑conjugated  goat  anti-­‐‑rabbit  or  anti-­‐‑
mouse  IgG  (Santa  Cruz)  at  1:2000  or  1:5000  dilutions,  respectively.  Blots  were  developed  
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with  ECL  and  proteins  quantified  by  densitometry  of  digitized  images  from  the  mid-­‐‑
dynamic  range  using  the  QuantityOne  program  (and  expressed  relative  to  GAPDH  or  
tubulin.  
Real-­‐‑time  PCR  and  gene  expression    
Total  cardiac  RNA  was  isolated  from  tissue  using  Trizol  Reagent  (Invitrogen,  
Carlsbad,  CA).  Mouse  liver  RNA  was  additionally  treated  with  turbo  DNA-­‐‑free  kit  
(Ambion)  using  the  protocol  for  rigorous  treatment.  Synthesis  of  cDNA  was  performed  
with  the  ImProm-­‐‑II  Reverse  Transcriptase  system  (Promega)  according  to  product  
instructions.  Reactions  to  quantify  per  sample  levels  of  TNF-­‐‑α,  IL-­‐‑6,  IL-­‐‑1β,  ICAM-­‐‑1,  and  
cytochrome  b  in  mouse  liver  and  heart  were  carried  out  on  a  7700  Sequence  Detector  
System  (Applied  Biosystems)  using  Taqman  Master  Mix  as  described  [60].  TLR-­‐‑4  mRNA  
expression  was  determined  as  described  [175]  using  gene-­‐‑specific  primer  pairs  [136].  
Expression  of  Hmox1,  Nos2,  TNF-­‐‑α,  IL-­‐‑6,  IFN-­‐‑γ,  and  IL-­‐‑10  genes  in  mouse  liver  (Figures  14  
and  15)  and  liver  cell  lines  was  quantified  using  the  StepOne  Plus  Real-­‐‑Time  PCR  system  
(Applied  Biosystems).    Each  sample  was  assayed  in  duplicate  and  mean  values  were  
reported.  The  RNA  data  were  normalized  to  18S  rRNA  expression  levels.  
Mitochondrial  isolation,  respiration,  and  DNA  copy  number  
Intact  mitochondria  were  isolated  from  fresh  hearts  using  sucrose  density  
centrifugation  [59].  Respiration  was  measured  at  35  °C  in  water-­‐‑jacketed  cuvettes  with  
calibrated  polarographic  oxygen  electrodes  (Diamond  General,  Ann  Arbor,  MI)  using  
0.5  mM  ADP  and  either  succinate  (5  mM)  or  malate+  glutamate  (2.5  mM  each)  as  
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substrates.  MtDNA  was  isolated  from  intact  mitochondria  [56,  175]  and  the  copy  
number  quantified  using  real-­‐‑time  PCR  for  cytochrome  b  (cyt  b)  as  described  [60].  
Samples  were  analyzed  in  triplicate  and  the  mtDNA  copy  number  per  nanogram  total  
cellular  DNA  was  reported  by  logarithmic  expression  relative  to  known  DNA  standards.  
Immunofluorescence  microscopy    
Four-­‐‑micrometer,  formalin-­‐‑fixed,  paraffin-­‐‑embedded  cardiac  sections  were  
processed  for  immunostaining  as  described  [68].  Anti-­‐‑TLR4  (StressGen)  and  anti-­‐‑NOS2  
(Upstate)  primary  antisera  were  used  at  a  working  dilution  of  1:100.  Conventional  
fluorescence  images  were  obtained  using  a  Nikon  Microphot-­‐‑FXA  fluorescence  
microscope.  MtGFP-­‐‑tg  was  visualized  in  green  fluorescence  and  all  other  proteins  in  red  
fluorescence.    
MTT  Assay  
Cell  viability  and  metabolic  activity  were  evaluated  using  the  colorimetric  (MTT)  
kit  from  Millipore  (Billerica,  MA).  Cells  were  grown  in  96-­‐‑well  plates  to  70-­‐‑80%  
confluence.  Treatments  were  given  as  described  for  cell  culture  experiments  above.  Two  
or  24  hours  after  LPS,  0.01  mL  MTT  reagent  (3-­‐‑(4,5-­‐‑dimethylthiazol-­‐‑2-­‐‑yl)-­‐‑2,5-­‐‑diphenyl  
tetrasodium  bromide)  was  added  to  each  well,  mixed  gently,  and  incubated  at  37°C  for  
four  hours.  To  facilitate  color  development,  0.1  mL  isopropanol  with  0.04  N  HCl  was  
added  to  each  well  and  plates  were  read  within  one  hour.  The  BioTek  Synergy  2  
microplate  reader  (BioTek,  Winooski,  VT),  courtesy  of  Dr.  Herman  Staats,  was  used  to  
obtain  absorbance  values  at  570  nm  with  reference  of  630  nm.    
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Statistics  
Group  values  were  expressed  as  means  ±  SD.  The  n  values  refer  to  independent  
samples.  Data  analyses  were  performed  using  Excel  to  calculate  Student'ʹs  unpaired  t  test  
and  GraphPad  Prism  5  to  calculate  2-­‐‑way  ANOVA  followed  by  Bonferroni  post-­‐‑tests.  
Regression  analyses  were  performed  using  Statview  (SAS,  Version  5.0.1).  A  p<0.05  was  
considered  significant.  
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